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Abstract——Chronotherapeutics aim at treating ill-
nesses according to the endogenous biologic rhythms,
which moderate xenobiotic metabolism and cellular
drug response. The molecular clocks present in indi-
vidual cells involve approximately fifteen clock genes
interconnected in regulatory feedback loops. They are
coordinated by the suprachiasmatic nuclei, a hypotha-
lamic pacemaker, which also adjusts the circadian
rhythms to environmental cycles. As a result, many
mechanisms of diseases and drug effects are controlled
by the circadian timing system. Thus, the tolerability of
nearly 500 medications varies by up to fivefold according
to circadian scheduling, both in experimental models
and/or patients. Moreover, treatment itself disrupted,
maintained, or improved the circadian timing system as
a function of drug timing. Improved patient outcomes
on circadian-based treatments (chronotherapy) have
been demonstrated in randomized clinical trials, espe-
cially for cancer and inflammatory diseases. However,
recent technological advances have highlighted large
interpatient differences in circadian functions resulting
in significant variability in chronotherapy response. Such
findings advocate for the advancement of personalized
chronotherapeutics through interdisciplinary systems
approaches. Thus, the combination of mathematical,
statistical, technological, experimental, and clinical
expertise is now shaping the development of dedicated
devices and diagnostic and delivery algorithms enabling
treatment individualization. In particular, multiscale
systems chronopharmacology approaches currently
combine mathematical modeling based on cellular and
whole-body physiology to preclinical and clinical
investigations toward the design of patient-tailored
chronotherapies. We review recent systems research
works aiming to the individualization of disease
treatment, with emphasis on both cancer management
and circadian timing system–resetting strategies for
improving chronic disease control and patient outcomes.
I. Introduction: Systems Approaches to
Optimize Chronotherapeutics
Broad interpatient variability in diseases and re-
sponse to treatments has become increasingly appar-
ent, so that personalizing medicine appears to be
needed to ensure maximum treatment efficacy and
minimum unwanted toxicities. However, a recent
appraisal cautions the lack of consistent clinical bene-
fits using the current personalized medicine concepts
(Tannock and Hickman, 2016). Optimizing therapeutic
strategies should hence encompass both the specificities
of the patient’s pathology and the patient’s genetics and
lifestyle (Khera et al., 2016; Califano and Alvarez,
2017). To this end, multitype and multiscale datasets
ABBREVIATIONS: AIC, 4-amino-5-imidazole-carboxamide; CBT, cognitive and behavioral therapies; CHK, check; CK, casein kinase; CRC,
colorectal cancer; CTS, circadian timing system; DDE, delay differential equation; EGFR, epidermal growth factor receptor; FBS, fetal bovine
serum; FdUMP, fluorodeoxyuridine monophosphate; 5-FU, 5-fluorouracil; IFN, interferon; mCRC, metastatic CRC; MR, modified release;
MTIC, 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide; ODE, ordinary differential equation; PD, pharmacodynamics; PDE, partial
differential equation; PK, pharmacokinetics; QT, interval between the start of the Q wave and the end of the T wave in the heart’s electrical
signal; SCN, suprachiasmatic nuclei; TMZ, temozolomide; TNF, tumor necrosis factor; TOP1, topoisomerase 1; TS, thymidylate synthase;
UGT, UDP-glucuronosyltransferase.
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have been generated in preclinical studies in cell
cultures and in laboratory animals, and in clinical
investigations involving populations of patients or in-
dividual subjects (Alvarez et al., 2016). The large
volumes of data that are thus generated across species
require dedicated approaches to properly analyze each
individual dataset, to handle the complexity arising
from multiple data types and dimensions, and to finally
translate the results into individualized therapies. The
rise of genomics and the accumulation of large amounts
of data and longitudinal and dense multidimensional
time series have paved the way for a new systems-based
approach to biology. Systems approaches are defined in
this work as interdisciplinary methodologies combining
mathematical, statistical, technological, experimental,
and clinical expertise for the development of dedicated
devices, theoretical algorithms, and clinical protocols
enabling treatment individualization.
Systems medicine involves the implementation of
such systems biology approaches in medical concepts,
research, and practice, through iterative and reciprocal
feedback between clinical investigations and practice
and computational, statistical, and mathematical anal-
ysis, as it has been emphasized in the Roadmap of
the Coordinated Action for Systems Medicine (CaSyM)
from the European Union (https://www.casym.eu), and
other consortia (Anderson and Quaranta, 2008; Agur
et al., 2014; Wolkenhauer et al., 2014; Iyengar et al.,
2015). The aim is a novel appraisal of pathogenetic
mechanisms, disease progression and remission, dis-
ease spread and cure, treatment responses and ad-
verse events, as well as disease prevention both at the
epidemiologic and individual patient level (CaSyM,
2014). Indeed, systems medicine aims at a measurable
improvement of patient health through systems-based
approaches and practice, which will enable a more
predictive, personalized, participatory, and preventive
(P4) medicine (Hood and Friend, 2011; Boissel et al.,
2015).
Many rhythms have been found in all living beings,
with periods ranging from milliseconds to years
(Halberg, 1969). Although endogenicity characterizes
biologic rhythms irrespective of period length, the
molecular mechanisms at work can vary largely among
the several kinds of biologic oscillators that reside in
cells, tissues, organs, and whole organisms (Goldbeter
et al., 2010). Systems chronotherapeutics aim at
encompassing this underlying complex system and its
dynamics toward the optimization of circadian-based
treatment on patient-specific bases. To this end, exper-
imental, translational, clinical, and multiscale model-
ing investigations have jointly aimed at representing
the circadian control in healthy organs involved in drug
pharmacology (e.g., hepatic metabolism, renal clear-
ance) and/or most susceptible to being injured, as well
as in diseased tissues (Bass and Lazar, 2016; Mermet
et al., 2016; Panda, 2016).
In this study, we first describe the mammalian
circadian timing system (CTS) and recent methods to
longitudinally assess it at multiple levels in cell culture,
laboratory animals, and individual patients, as a pre-
requisite for multiscale theoretical approaches. Then
we provide the current state of the art of preclinical and
clinical chronotherapeutics, and available technologies
for chronomodulated drug administration. Next, we
review recent systems approaches to optimize and
personalize chronotherapeutics and show their rele-
vance for improving cancer therapy. The potential of
systems chronotherapeutics is further illustrated for
cardiovascular, metabolic, and inflammatory disorders.
The issue of CTS disruption is then addressed, re-
garding its clinical impact and the theoretical methods
that could help design clocks resetting and synchroniz-
ing strategies. Finally, we discuss the current chal-
lenges toward a translation of systems approaches into
the clinics.
II. The Circadian Timing System and Its
Multilevel Intersubject Variabilities
Timekeeping systems can be found in the vast
majority of organisms on Earth, and they are believed
to confer a selective advantage (Woelfle et al., 2004;
Spoelstra et al., 2016). These biologic clocks most likely
have evolved to anticipate recurrent daily changes in
environmental conditions caused by the earth’s rotation
around its own axis. With a period of about 24 hours
(Latin: circa = about, dies = day), endogenous circadian
clocks prepare organisms for important daily events
such as the availability of food or changes in environ-
mental temperature by orchestrating behavior and
physiology before these events occur. In mammals,
many biologic functions are modulated by the CTS as
a consequence of endogenous temporal regulations at
various levels influenced by external cues (Fig. 1).
A. Structure of the CTS
1. The Whole-Hierarchical Organization. The CTS
is the entirety of all oscillators in an organism and their
coupling through various physiologic processes. How-
ever, not all clocks are equal. The central or master
pacemaker of the CTS resides in the suprachiasmatic
nuclei (SCN) located in the ventral hypothalamus.
They display endogenous circadian oscillations both at
the cell and tissue levels and in their outputs toward
other organs. Ablation of the SCN leads to arrhythmic
behavior, physiology, and hormonal secretions (Moore
and Eichler, 1972; Stephan and Zucker, 1972). Various
mechanisms for how the circadian information is then
transmitted to the rest of the body have been elucidated.
The SCN exert a control on the organism through the
rhythmic regulation of physiologic processes, including
temperature, hormonal levels, and/or the autonomous
nervous system (Lévi and Schibler, 2007). Melatonin, a
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hormone that is released by the pineal gland, is
one example of a multisynaptic output of the SCN
(Tordjman et al., 2017). It is widely used as a phase
marker for the SCN, and, interestingly, its secretion has
been shown to feedback on the SCN (Shimomura et al.,
2010). At the peripheral level, each nucleated cell is
endowed with a molecular circadian clock that gener-
ates autonomous intracellular circadian variations and
is under the control of both SCN-driven systemic and
tissue-level factors. In physiologic conditions, the oscil-
lators in this complex interacting system display stable
and well-defined phase relationships with each other.
In fact, multiorgan high-density time course experi-
ments in mice have revealed that at least the core clock
genes exhibit similar phases throughout at least a
dozen different tissues (Zhang et al., 2014b). Although
a growing number of pathways for resetting cellular
clocks are discovered, it is largely unknown how all of
these interact in vivo and how the various tissues
maintain coherent phase relationships with each other
and with the environmental cycles. A number of
possible mechanisms have already been proposed, and
most likely all of these signals contribute in a tissue-
specific manner (Schibler et al., 2015).
To be useful for anticipating environmental changes
or specific events, the organism has to synchronize its
clocks with outside cues. There are various of these
so-called Zeitgeber (German for “time givers”) or syn-
chronizers that entrain the CTS components to a robust
24-hour rhythm by resetting the phase or influencing
the amplitude of the CTS oscillators at the cellular
as well as organismal level (Fig. 1). One of the most
well-studied Zeitgeber is the alternation of light and
darkness over 24 hours. In mammals, light is exclu-
sively detected by the retina through classic photore-
ceptors as well as specialized retinal ganglion cells that
have direct monosynaptic connections into the SCN
(Peirson et al., 2005). Rest-activity patterns, including
sleep-wake cycles, familial and professional interac-
tions, and physical exercise, also influence the central
clock, whereas meal timing impacts metabolism-linked
peripheral clocks.
2. The Parts—Cellular Circadian Clocks. Under
physiologic conditions, presumably all mammalian cells
in the body possess a functional circadian oscillator. In
principle, the underlying molecular mechanism is a
negative feedback loop (Jolley et al., 2012). This basic
mechanism was first described in fruit flies (Hardin
et al., 1990). Although the players vary, the basic
building principle is conserved across phyla and can
be found in temporal variations in unicellular cyano-
bacteria as well as mammalian cells (Brown et al.,
2012). Interestingly, the clock genes that contribute to
the core transcriptional/(post-)translational feedback
loops have largely been found using forward genetic
N-ethyl-N-nitrosourea mutagenesis screens for domi-
nant mutations or targeted transgenics on homologs of
known clock genes in other organisms. Deletion or
mutation of most of these genes leads to strongly
disrupted circadian rhythms in behavior.
In mammals, the core clock genes of these oscillators
are known in great detail, and the mechanism is briefly
described below (Takahashi, 2017). The transcriptional
activator complex of BMAL1 and its partner CLOCK or
NPAS2 binds to short palindromic so-called E-box
elements in the promoter of PER and CRY repressor
Fig. 1. The CTS. The CTS is composed of a central pacemaker located in the SCN that displays autonomous circadian oscillations, but is also entrained
by external cues such as light or socioprofessional activities. The SCN further generate rhythmic physiologic signals exerting a control on the
autonomous molecular clocks present in each nucleated cell, which, in turn, induce oscillations in the expression of a large number of genes involved in
key intracellular processes.
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genes (DeBruyne et al., 2007). After translation and
post-transcriptional modifications, PER and CRY pro-
teins re-enter the nucleus as a complex and switch off
their own transcription, thereby closing the feedback
loop (Padmanabhan et al., 2012). After about 24 hours,
the repressor complex is removed and a new activation
cycle can begin. Interlocked with this first discovered
loop is a secondary or stabilizing loop. Driven by
transcriptional activation through BMAL1-containing
complexes, this loop is closed by direct REV-ERB and
retinoic acid–related orphan nuclear receptor feedback
on the transcriptional activity of BMAL1 through
retinoic acid–related orphan nuclear receptor elements
in the BMAL1 promoter (Guillaumond et al., 2005). The
period, amplitude, and phase of this oscillator are
largely determined by post-transcriptional modifica-
tions influencing nuclear transport or degradation of
the repressor complexes as for casein kinase (CK)1 and
E3 ligase activity of F-box proteins on PERs and CRYs
(Busino et al., 2007; Meng et al., 2008; Etchegaray et al.,
2009; Yoo et al., 2013).
Sumoylation (Cardone et al., 2005), acetylation (Doi
et al., 2006; Hirayama et al., 2007; Asher et al., 2008),
dephosphorylation (Reischl and Kramer, 2011), and
ubiquitination (DeBruyne et al., 2015) further post-
translationally regulate the clock proteins (Hirano
et al., 2016). Furthermore, epigenetic regulation has
been found to play a role in clock regulation (Papazyan
et al., 2016) and rhythmic changes in the chromatin
landscape of the DNA (Koike et al., 2012) and histone
and DNA modifications have been reported (Ripperger
andMerrow, 2011; Sahar and Sassone-Corsi, 2013; Azzi
et al., 2014), and so have splicing and RNAmodification
as well as ribosomal translation (McGlincy et al., 2012;
Lim and Allada, 2013; Perez-Santangelo et al., 2014;
Jang et al., 2015; Janich et al., 2015).
All of these different layers of circadian regulation not
only drive the core clock mechanism but, importantly,
modulate many downstream processes (Chaix et al.,
2016). In fact, up to 40% of the transcriptome is thought
to oscillate with circadian period, and a similar pro-
portion of 20–40% of the proteome and metabolome has
also been found to exhibit circadian patterns (Dallmann
et al., 2012; Davies et al., 2014; Mauvoisin et al., 2014;
Robles et al., 2014; Zhang et al., 2014a; Giskeodegard
et al., 2015).
Importantly, this core clock mechanism is linked to
cellular functions on many levels. Although probably
more than one of the above-mentioned mechanisms is
responsible for this large proportion of rhythmic fea-
tures, E-boxes are probably the simplest and most
immediate way to control gene expression. It has to be
noted, however, that the phase of many circadian genes
is not only regulated by BMAL1:CLOCK binding to the
E-box but also various other transcription factors that
might change the phase of transcription possibly con-
veying tissue-specific regulation (Menet et al., 2012). In
addition, further mechanisms have been discovered to
tune phase and amplitude of clock-controlled genes in
peripheral tissues. microRNA tissue-specific regulation
of gene expression phase and amplitude was found (Du
et al., 2014). Some of these genes are transcription
factors, too, and control themselves as well as further
sets of genes with a different phase compared with
E-box–driven rhythmic genes (Bozek et al., 2007). The
intricate relationship of the circadian oscillator with
another highly controlled and rhythmic process, that is,
the cell cycle, is discussed in detail below. Of course, this
also has implications for apoptosis and the signaling
pathways involved in its induction (Lee and Sancar,
2011a,b).
B. Multiscale Circadian Assessment Enables
Systems Approaches
Systems approaches were enabled by the recent
development of experimental and clinical technologies
allowing for longitudinal continuous measurements
over several circadian periods of various components
of the CTS in a single cell, a population of cells, as well
as a laboratory animal, or a human subject in a nonre-
strained environment (Fig. 2).
1. Preclinical Longitudinal Circadian Studies toward
Systems Approaches. The rapid progress made in cell
culture synchronization methods, bioluminescence/
fluorescence reporter technology, and dedicated dy-
namic imaging developments has recently fostered
systems chronobiology and chronopharmacology stud-
ies. In particular, the use of real-time reporters allows
for a quantitative definition of circadian period, phase,
and amplitude of oscillations and thus can help in
uncovering even subtle phenotypes (e.g., Duong et al.,
2011). The cell transfection of multiple reporters and its
single-cell imaging have further enabled the experi-
mental investigation of the control of the molecular
circadian clock on intracellular pathways involved in
drug response (Feillet et al., 2014). Interestingly for the
systems approach are the multiscale applications of such
technologies that linkmechanistic insights to themolecular
clock in single cells or cell populations to whole organism
dynamical behaviors. Indeed, real-time recording of liver
gene expressions in freely moving individual mice has
recently been enabled by the development of new devices
(Saini et al., 2013). These technologies also called for the
design of dedicated statistical signal-processing methods
(Costa et al., 2013). Furthermore, with the availability of
various “omics” techniques, systems approaches to fur-
ther elucidate the circadian clock mechanism have been
attempted. Of course, big data have necessitated new data
mining strategies, and machine-learning algorithms have
contributed to more accurately define the molecular clock-
work (e.g., Anafi et al., 2014).
2. Longitudinal Assessment of the Human CTS
toward Personalized Medicine. Personalization sys-
tems approaches would not be possible without the
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recent development of technologies dedicated to assess
circadian rhythms in individual human subjects. The
patient’s CTS is either assessed through wearable
sensors recording continuous data for several days, or
through repeated measures, mainly in the blood, the
saliva, the breath, or the urine as multiple sampling of
any other human tissues would often be unpractical
and/or unethical. To properly evaluate circadian func-
tion, it is required to identify the most pertinent
circadian biomarkers and to design devices monitor-
ing them over several days or weeks with the least
discomfort for the patient. Generally, the most rele-
vant biomarker rhythms are constituted by those that
act also as resetting cues for the molecular peripheral
clocks, or that also signal the central pacemaker
(Innominato et al., 2014).
The rest-activity rhythm is the most widely assessed
in patients, because its pattern can be easily evaluated
using a small triaxial accelerometer (the actigraph),
worn most often on the wrist, but also on the arm,
thorax, hip, or ankle (Ancoli-Israel et al., 2003). Longi-
tudinal wrist-actigraphy monitoring in individual can-
cer patients has indeed demonstrated its validity for
prognosis prediction and for association with patient-
reported outcomemeasures (Mormont andWaterhouse,
2002; Payne, 2011; Lévi et al., 2014). Actigraphy is
particularly useful as it allows assessment of both
locomotor activity and sleep, which are relevant bio-
markers for many diseases (Broderick et al., 2014;
Madsen et al., 2015).
More recently, temperature rhythm measured
through thermal patches on the proximal (i.e., thoracic)
or distal (i.e., forearm) skin has demonstrated its
relevance in cancer patients (Roche et al., 2014; Ortiz-
Tudela et al., 2016). A new device simultaneously
recording rest-activity, position, and thoracic skin tem-
perature was tested in the pilot clinical study Picado
within a Domomedicine platform also monitoring pa-
tient daily weight variations and self-assessed quality
of life and symptoms (Maurice et al., 2015).
Wearable technologies have also been developed to
assess ECG and heart rate variability, as a surrogate of
autonomic nervous system balance in the short- or
medium-term (Melillo et al., 2015). Indeed, this bio-
marker has shown clinical value in hypertensive pa-
tients to predict fallers (Melillo et al., 2015) and in
cancer patients (Palesh et al., 2008; Giese-Davis et al.,
2015).
One of the most extensively assessed circadian
rhythms in patients is cortisol, an adrenal hormone
that can be easily measured in saliva as well as in blood.
Such rhythm had an independent prognostic role in
patients with breast, ovarian, kidney, or lung, but not
colorectal cancer (Sephton et al., 2000, 2013). However,
Fig. 2. Multiscale longitudinal assessment of the CTS. Recent technologies allow for the recording of biomarkers of the CTS at multiple scales: in
Per2::luc Hepa1-6 cell culture, imposed temperature cycles (A) and Per2 bioluminescence measured by Lumicycle (B); in individual B6D2F1 male mice
entrained in LD12:12, body temperature recorded by telemetry (C); and, in Per2::luc animals, bioluminescence recorded in RT-Bio (D); in individual
young male healthy volunteers, skin temperature recorded though new thoracic wearable sensors (E, In Casa project), and individual Per2 mRNA level
in peripheral blood mononuclear cells (F, dots are data from Teboul et al., 2005; dotted line is the best-fit cosinor model). Longitudinal measurement
over several days of molecular biomarkers is currently not available in the clinics, and multiscale systems approaches aim at predicting from
preclinical results and clinical investigations the patient-specific dynamical information needed for treatment personalization. Time is expressed in
days. Zero represents midnight (clock hours) on the first day of experiment.
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the vast majority of cortisol time series in patients only
involve diurnal samples, with few, if any, night samples.
To address this issue, a new sensor was developed that
allows for the continuous measurement over 3 con-
secutive days of cortisol in the skin interstitial fluid,
where cortisol levels are actually higher than in the
saliva (Venugopal et al., 2011). Melatonin rhythm
can also be measured in the saliva to assess the
amplitude and phase of the central pacemaker with
implication in various diseases, including brain in-
juries or sleep-wake disorders (Sletten et al., 2010;
Burgess et al., 2015; Grima et al., 2016). Next, the
least invasive way to monitor the transcriptional
output of the molecular clock is to measure the
expression profiles of core clock genes in peripheral
blood mononuclear cells (Fig. 2). This approach is
feasible in healthy subjects (Boivin et al., 2003;
Takimoto et al., 2005), albeit atypical patterns can
be found (Teboul et al., 2005), and only scarce data
are available in patients. Finally, plasma, saliva,
or even breath circadian “omics” datasets such as
transcriptome and metabolome are now available in
humans (Dallmann et al., 2012; Martinez-Lozano
Sinues et al., 2014).
C. Multilevel Intersubject Variability in the Human
CTS Advocating for Personalized Chronotherapeutics
The timing of several circadian rhythms can vary
among individuals with respect to sex, age, genetic
background, and lifestyle (Ortiz-Tudela et al., 2013).
Epidemiologic large-scale studies using the Munich
Chronotype Questionnaire in more than 55,000 human
subjects revealed large variation in behaviors within
the 24-hour span (Roenneberg et al., 2007). Wrist
actigraphy has further uncovered large intersubject
differences in circadian phase and amplitude in a pooled
analysis involving 436 patients with metastatic colorec-
tal cancer. For instance, the circadian maximum in the
activity of these patients was spread over a 10-hour
span (Innominato et al., 2014). Moreover, interpatient
differences of up to 12 hours were found in the circadian
acrophase of skin surface temperature rhythms in
24 metastatic gastrointestinal cancer patients (Roche
et al., 2014; Ortiz-Tudela et al., 2016).
Strong experimental and clinical evidence suggests
that these interindividual differences in circadian phys-
iology might translate at the molecular clock level
(Cermakian and Boivin, 2003). The phase and ampli-
tude of mRNA levels of PER2, BMAL1, and REV-ERBa
expression measured over 24 hours through repeated
sampling of peripheral blood cells of healthy youngmale
subjects greatly varied among subjects, although this
was not captured in wrist activity (Teboul et al., 2005).
New real-time reporter techniques have also been
instrumental to further discover significant variations
in the in vitro circadian period of human fibroblasts
taken from healthy individuals as a surrogate for in vivo
human diurnal preferences (Brown et al., 2008; Pagani
et al., 2010). Furthermore, the circadian expression of
nearly 2000 genes in the oral mucosa differed between
healthy male and female human subjects (Bjarnason
et al., 2001). Moreover, findings showing that alle-
lic variation of clock genes can influence the indi-
vidual timing of cellular responses to wide range of
environmental stimuli (Benedetti et al., 2008) suggest
that optimal treatments should follow an individual
optimization.
III. Chronotherapeutics
Chronotherapeutics is the science of preventing
or treating illnesses according to biologic rhythms
(Halberg, 1973). It involves the timing of pharmaco-
logical and nonpharmacological interventions, such
as surgery, physical agents, and psychotherapy. The
goal is to minimize toxicity or adverse events, and/or
to enhance treatment efficacy through adequate treat-
ment timing and shaping (Sancar et al., 2015; Selfridge
et al., 2016). More recently, chronotherapeutics has also
aimed at targeting treatments toward the rhythm-
generating biologic timing systems, to improve out-
comes through amplification, dampening, alteration,
or resetting. Although some treatment schedules in-
volve the delivery of medications according to rhythms
with periods usually ranging from 1 to 6 hours, so called
ultradian (Belchetz et al., 1978; Chen et al., 2016),
chronotherapeutics has mostly considered the implica-
tions of the CTS for treatment effects (Lévi and Schibler,
2007; Lévi et al., 2010; Lévi and Okyar, 2011; Dallmann
et al., 2014, 2016). As a result, the current review
focuses on circadian chronotherapeutics.
The demonstration that circadian rhythms were
endogenous led to investigate the implications of the
temporal organization of biologic functions for drug
effects in preclinical models. Experiments in the
1960–1970s demonstrated up to several-fold reproduc-
ible changes in toxicity as a function of circadian timing
of a fixed dose of methopyrapone, an adrenal cortical
inhibitor (Ertel et al., 1964); morphine, an analgesic
(Morris and Lutsch, 1967); lidocaine hydrochloride, an
anesthetic and antiarrhythmic (Lutsch and Morris,
1967); ouabain, an antihypotensive (Nelson et al.,
1971); methadone, an anti-addiction agent (Lenox and
Frazier, 1972); arabinosylcytosine, an antimetabolite
cytostatic (Haus et al., 1972); cyclophosphamide, an
alkylating cytostatic (Haus et al., 1974); or lithium, an
antidepressant and mood regulator (Hawkins et al.,
1978). Although the potential implications for reducing
adverse events of treatments were already emphasized,
the results generated lively scientific controversies,
which usually resulted from methodological issues
regarding animal characteristics, synchronization,
and manipulations (Lévi and Schibler, 2007). Their
implementation has resulted in the demonstration of
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circadian time–dependent pharmacology for over
400 medications, including nearly 50 anticancer agents
administered via i.v., i.p., s.c., or oral routes in mice or
rats (Lévi et al., 2010; Dallmann et al., 2016).
A. Chronopharmacology
The observed and measurable rhythms in drug
tolerability and/or efficacy led to question the mecha-
nisms at work regarding the relevance of both the
rhythmic exposure to the drug and its metabolites
(chronoPK) and the rhythmic organization of drug
targets (chronoPD) (Reinberg and Halberg, 1971;
Bruguerolle, 1998; Lemmer, 2005; Lévi and Schibler,
2007; Lévi et al., 2010; Lévi and Okyar, 2011; Dallmann
et al., 2014, 2016).
1. Chronopharmacokinetics. Twenty-four–hour
changes have been demonstrated for each of the
processes that determine drug disposition, that is,
absorption, distribution, metabolism, and elimination
and/or their toxicities (Fig. 3) (Bruguerolle, 1998;
Lemmer, 2005; Lévi and Schibler, 2007). Such chro-
noPKmoderate the exposure dynamics of target tissues
to bioactive drug metabolites, irrespective of drug class,
route of administration, residence time, or single versus
repeated dosing schedule (Lévi and Schibler, 2007).
However, the physicochemical properties of a medica-
tion can modify its absorption parameters and affect its
dosing time dependency (Lemmer, 2005). Large circa-
dian time dependencies can also characterize the
pharmacokinetics (PK) of sustained release prepara-
tions of several medications both at steady state and
during prolonged constant rate infusions. The 24-hour
changes in absorption, distribution, metabolism, and
elimination and/or their toxicities result from a host of
physiologic rhythms, including gastric pH; gastric and
small intestinal motility; plasma proteins and protein
subtypes; membrane microviscosity; receptor density or
binding enzymatic activities, transport proteins and ion
channels, limb, liver, and renal blood flows; liver me-
tabolism; and bile volume and salt excretion, as well as
renal glomerular filtration rate, tubular reabsorption
rate, and urinary output and pH (Lévi and Schibler,
2007; Dallmann et al., 2016). The relevance of circadian
timing for drug persists in fasting rodents or humans.
Yet, food intake or composition can modify the aver-
age PK parameters, yet only slightly alter the over-
all chronoPK profile (Bruguerolle and Prat, 1989).
An imposed feeding pattern, however, can shift the
Fig. 3. Circadian control of drug PK-PD. The CTS regulates drug transport at various levels, including intestinal absorption, intracellular uptake and
efflux, and renal and intestinal excretion. Similarly, the amount of protein and metabolite binding to drugs in the plasma varies according to circadian
time. Regarding PD, most systems of the organism are under the control of the CTS at the molecular, cellular, and physiologic levels. They can either be
altered in specific diseases and impact on drug chronoefficacy or be involved in drug tolerability as targets of dose-limiting toxicities.
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synchronization of peripheral clocks, especially in the
digestive system (Damiola et al., 2000), thus shifting the
chronopharmacological profile of a drug accordingly.
2. Cellular Mechanisms of ChronoPK. On the cellu-
lar level, the genetic clock directly controls the tran-
scription of key rate-limiting steps in many metabolism
pathways. Clock-controlled proline and acidic amino
acid-rich basic leucine zipper transcription factors, such
as albumin D-box albumin-binding protein, hepatic
leukemia factor, and thyrotroph embryonic factor,
further bind rhythmically to D-box–containing pro-
moters of key genes that regulate xenobiotic metabo-
lism. These includePORs,ALAS,CAR,PPAR, andAhR.
Indeed, the expression of CYPs, ALAS1, and PORmust
be coordinated to permit efficient detoxification. Thus,
the molecular clock redundantly and rhythmically
controls Phase I reactions, including the PORs and the
CESs (Gachon et al., 2006; Ballesta et al., 2011). The
molecular clock further directly and indirectly controls
the Phase II detoxification systems, including UGTs,
N-acetyltransferases, and the reduced glutathione cycle
(Gachon et al., 2006), as well as the Phase III trans-
porters, such as ABCB1 (P-gp), ABCC2, and ABCG2
(Murakami et al., 2008; Zhang et al., 2009b; Okyar et al.,
2011). Members of Phase I, II, and III families, as well
as ALAS1 and POR, displayed circadian expression at
enzymatic activity, protein, and/or mRNA levels. A
recent study showed that conditional deletion of Bmal-1
in renal tubular cells of adult mice impacted both
renal transcriptome and plasma metabolome and in-
duced a decrease of 80% in the protein expression of
organic anion transporter 3, which was paralleled by a
reduced kidney excretion of the anionic drug furosemide
(Nikolaeva et al., 2016). The circadian control of phar-
macological enzymes may also originate from the
masterclock as for CYP P450 genes in the mouse liver,
which were found to be regulated through neuropeptide
Y, the latter being driven by SCN-derived signals rather
than by the cellular clock (Erion et al., 2016). Hence, the
regulation of xenobiotic detoxification is complex, in
that the expression of Phase I, II, and III components,
ALAS1, and POR can be cell-type–specific, daytime-
dependent, and substrate-inducible. Several of the
above-mentioned transcription factors either accumu-
late in a circadian manner, display circadian activity, or
are induced in a daytime-dependent manner (Richardson
et al., 1998; Gachon et al., 2006).
3. Chronopharmacodynamics. Drug activity is mod-
ulated by the circadian rhythms of 1) its direct in-
tracellular target and triggered pathways and 2) the
extracellular environment circadian status as a result of
the control by the CTS of most physiologic functions,
including the cardiovascular, immune and inflamma-
tory, energy regulation, and nervous systems (Fig. 3).
Studies involving the in vitro exposure of cells, obtained
at different circadian times, to anticancer agents, have
first identified cellular rhythms as major pharmacology
determinants. As an example, bone marrow cells were
sampled frommice at six different times. The cells were
then cultured in the presence of different concentrations
of theprubicin, a topoisomerase II inhibitor. Large-
amplitude 24-hour rhythms characterized the in vitro
cytotoxicity of this agent at several dose levels that were
tested. The in vitro chronotoxicity of theprubicin
for hematopoietic progenitors matched the in vivo he-
matologic chronotoxicity, following theprubicin i.v.
delivery into mice (Lévi et al., 1988). Indeed, an
endogenous circadian rhythm characterized the pro-
liferative response of mouse bone marrow cells to
granulo-monocytic colony-stimulating factor. Such
chronopharmacology was demonstrated whether this
hematopoietic growth factor was delivered to fresh
bone marrow cells obtained at different circadian
times, or to bonemarrow cells cultured for up to 4 days
and exposed at different circadian times (Perpoint
et al., 1995; Bourin et al., 2002).
B. Clinical Relevance of Chronotherapeutics
Several Phase III clinical trials testing chronotherapy
versus conventional non–time-stipulated treatment
schedules have resulted in up to fivefold better tolera-
bility and a near doubling in efficacy (Dallmann et al.,
2016). Meta-analyses of chronotherapy schedules have
further suggested a survival benefit in male patients
(Giacchetti et al., 2012). However, a number of random-
ized comparisons between morning and evening dosing
times have shown similar rates of toxicities and/or
efficacy for several drugs (Dallmann et al., 2016). These
findings suggest that either the study designmissed the
optimal timing, excessive or insufficient dose levels
were tested, or interpatient differences masked the
circadian timing effects. For instance, some trials have
assessed the effects of drug timing by grouping patients
receiving drugs of the same class (e.g., angiotensin
receptor blockers, calcium channel blockers), although
each of the molecules in a given class likely presents
different chronoPK-PD and chronotoxicity patterns as
demonstrated for anticancer cytototoxic agents (Lévi
et al., 2010; Stranges et al., 2015). Furthermore,
experimental and clinical data have revealed broad
interindividual CTS differences, resulting in different
chronotoxicity profiles. Such differences can result from
genetically determined chronotypes as well as from
epigenetic changes, age, sex, lifestyle, disease, or phar-
macological treatment, as discussed further in this
review. Pioneering studies have, however, highlighted
the relevance of morning dosing of glucocorticoids to
minimize adverse events, resulting from adrenal sup-
pression, resulting in the current timing recommenda-
tions for glucocorticoid intake in daily medical practice.
Evening dosing has been recommended for most the-
ophylline preparations to enhance bronchodilation
and reduce side effects in asthmatic patients. How-
ever, morning dosing was shown to be more effective
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and safer for a sustained release preparation of the-
ophylline (Smolensky et al., 2007). Similarly, evening
dosing has been recommended for several anti- H1
and anti-H2 antihistamines in allergic and gastritis
subjects, respectively, as being both more effective and
better tolerated. For instance, the oral intake of 10 mg
mequitazine provided more effective symptom relief
than morning intake in a double-blind randomized
trial involving patients with severe seasonal rhinitis
(Smolensky et al., 2007). Clinical studies have also
revealed the relevance of circadian rhythms for antico-
agulant therapy in patients with thrombo-embolic
disorders, while emphasizing the occurrence of rhyth-
mic and nonrhythmic patients regarding heparin chro-
nopharmacology (Decousus et al., 1985).
A recent study investigated the time of administra-
tion recommendations on chronotherapy for 30 com-
monly prescribed medicines in Australia (Kaur et al.,
2016). In 56% of 27 research studies matching inclusion/
exclusion criteria, the therapeutic effect of the medi-
cine varied with the time of administration, that is,
supported chronotherapy. For some medicines (e.g.,
simvastatin in the evening), circadian-based optimal
administration time was evident in the information
sources. Indeed, the circadian PK-pharmacodynamics
(PD) of a drug can profoundly impact on its efficacy and
tolerability, as illustrated for patients with cancer in
Chapter 5, and rheumatologic, cardiovascular, or met-
abolic diseases in Chapter 6.
C. Technology for Circadian Drug Delivery
Clinical chronotherapeutics have motivated both the
development of programmable-in-time drug delivery
pumps and the design of new drug formulations aiming
at targeting specific circadian time windows. These
recent technologies, together with the development of
forecasting methods, are an important prerequisite for
successfully translating the results of theoretical ap-
proaches into the clinics.
1. Programmable-in-Time Infusion Pumps. Conven-
tional infusion protocols of cancer chemotherapy only
consider drug doses, duration, and frequency of infu-
sions. As a result, treatment times often vary among and
within patients, yet mostly between 9:00 and 17:00,
that is, over only one-third of the day span, for hospital
logistics reasons. In contrast, circadian chronomodu-
lated schedules stipulate the time courses and pa-
rameters of the delivery profile for each anticancer
medication over the 24-hour period to achieve the best
therapeutic index, according to biologic rhythm-based
specifications. This includes times of onset and offset of
infusion and variation of flow rate, ranging from
constant to sinusoidal or gradually increasing or de-
creasing. These new concepts of drug delivery have
triggered the industrial development of nonimplantable
multichannel programmable-in-time pumps, which in
turn have fostered the clinical development of cancer
chronotherapeutics. Multiple circadian infusion sched-
ules are then jointly administered to nonhospitalized
patients, with minimal or no medical or nursing in-
tervention. The advent of the IntelliJect device with
four 30-ml reservoirs enabled the development of the
first combination schedule of 5-fluorouracil (5-FU)–
leucovorin–oxaliplatin and led to the initial demonstration
of the safety and efficacy of this three-drug chemother-
apy given according to a circadian-chronomodulated
delivery schedule, several years before the registration
of oxaliplatin (Lévi et al., 2010). Melodie, a second
generation of electronically engineered four-channel
programmable pumps, represented considerable tech-
nological progress, through increased energy autonomy,
flexible reservoir capacity, rapid programming of any
delivery schedule, computer storage of treatment proto-
cols and patient data, as well as actual drug delivery
reports for each treatment course. The infusion pressure
of this pump allowed the safe and effective administra-
tion of irinotecan–5-FU–oxaliplatin in a European trial
involving conventional or chronomodulated three-drug
infusions into the hepatic artery (OPTILIV) (Lévi et al.,
2016). This device is currently being upgraded to become
the first connected e-chronopump. Further applications
are foreseen for chronic antibiotic or nutrition delivery,
among others.
2. Modified Release of Oral Drugs. Chronotherapeu-
tics concepts have further elicited the development
of cutting-edge technologies for modified release (MR)
drug formulations aiming at selective tissue exposure at
the desired time window over the 24 hours (Khan et al.,
2009; Patel, 2015). For instance, the physiologic noc-
turnal high values of plasma melatonin were mimicked
with Circadin, a melatonin formulation that releases
this hormone over 5–7 hours following evening intake
(Lemoine and Zisapel, 2012). Similarly, a MR formula-
tion of prednisone was developed to achieve sustained
low-dose tissue exposure during the early night span,
following evening intake, and a rise in plasma levels
starting near 4:00, to culminate around 8:00, and
decreased gradually thereafter, thus mimicking the
physiologic circadian pattern of cortisol secretion
(Henness and Yang, 2013). Such chronomodulated re-
lease of prednisone would further counteract the proin-
flammatory cytokines that are usually released at
night, and contribute to the early morning joint in-
flammation that characterizes rheumatoid arthritis.
Indeed, MR prednisone decreased by 20% dis-
ease symptoms compared with placebo when associ-
ated to standard antirheumatic drugs and achieved a
better reduction of morning stiffness compared with
immediate-release prednisone (Henness and Yang,
2013). Other drug formulations aim at achieving a
delayed peak exposure in the early morning when the
drug is administered before going to bed to prevent
acute events in the early morning. For instance, con-
trolled pulsatile release capsules of montelukast sodium
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were developed for the prevention of episodic attack of
asthma in the early morning and associated allergic
rhinitis (Ranjan et al., 2014). It is also possible to
combine several active compounds in the same formula-
tion to insure specific delays in between each drug
exposure. For instance, a multilayered multidisc tablet
comprising two agents enveloped by drug-free barrier
layers was developed in the context of chronotherapeutic
disorders, employing two model drugs, theophylline and
diltiazem, and provided two pulses of drug release (Khan
et al., 2013). Apart from oral administration, trans-
dermal technologies have been developed to achieve
proper drug release timing according to skin tempera-
ture (Malik et al., 2008; Hammann et al., 2016). This
formulation has the advantage to adapt to the individual
patient’s temperature rhythms allowing personalized
drug timing.
3. Toward Rhythm-Sensing Drug-Releasing
Nanoparticles. Inter- and intrapatient variability crit-
ically impact on the tolerability and efficacy of drugs
given at their recommended dose level. For instance,
systemic drug exposure can vary more than 10-fold in
individual patients, despite dose adjustment to body
weight or surface area. Such variability greatly limits
the success rate of pharmacotherapies. Although chro-
nomodulated delivery at fixed time appeared to reduce
such intersubject variability in maximum plasma drug
levels, as shown for 5-FUand oxaliplatin (Metzger et al.,
1994; Lévi et al., 2000), it did not eliminate CTS
differences among subjects, resulting in important dif-
ferences in drug elimination kinetics (Kwiatkowski
et al., 2003). Novel nanotechnology-based approaches
could link drug release to a relevantmolecular circadian
rhythm in the cells of interest. This would achieve
effective delivery of chronotherapy according to individ-
ual patient rhythms independently from drug timing.
Rhythmic trigger-elicited drug formulation could pre-
sent a great benefit particularly in the field of cancer
research, as anticancer chemotherapy commonly re-
sults in dose-limiting adverse events, thus favoring
acquired resistance, poor efficacy, and poor patient
outcomes.
IV. Systems Approaches toward
Personalized Chronotherapeutics
What is meant by systems approaches could be
defined by the use of mathematical and statistical
methods to analyze multitype and multiscale datasets.
In the context of chronotherapeutics optimization, those
pluridisciplinary pipelines mostly aim at designing
patient-specific drug combinations and administration
schedules. We first review the different mathematical
models representing the circadian control of the follow-
ing: 1) intracellular pathways within a single cell and 2)
the dynamics of a whole cell population, in the absence
of drug. Those models can represent either diseased or
healthy cells/organs, and the next step toward thera-
peutic optimization consists in representing the drug
chronoPK-PD on these tissues. We further explain why
it is crucial to base the pharmacological modeling on the
cell/organ physiology as it allows for multiscale ap-
proaches ultimately leading to reliable clinical models
that provide the basis for a personalization algorithm.
A. Multiscale Modeling of the Circadian Control of
Healthy and Diseased Tissues
Mathematical modeling has aimed at knowledge
improvement regarding the multilevel interactions be-
tween the CTS and the peripheral tissues to predict
drug chronopharmacology and chronotoxicity. To en-
sure the clinical translation of experimental findings,
multiscale methodologies are required in which living
organisms are not subdivided down into independent
components, but rather, it is recognized that genes,
proteins, cells, and organs interact with each other and
with the environment in complex ways that can vary
over time (CaSyM, 2014). To properly address these
issues, there is a need to consider first at the single-cell
level the molecular circadian clock and the oscillatory
dynamics generated in other cellular functions, such as
the cell cycle, another critical determinant of many drug
effects. Next, single-cell models need to be integrated
into representations of cell populations to assess phar-
macological effects at the tissue scale.
1. Single-Cell Level.
a. The molecular circadian clock. As described
above, the molecular circadian clock is an intracellular
network involving approximately 15 genes interlinked
in several feedback loops resulting in an autonomous
oscillatory system. Several mathematical models of the
cellular clock have been developed involving different
levels of complexity, reviewed in (Ukai and Ueda, 2010;
Bordyugov et al., 2013; Ortiz-Tudela et al., 2013). Some
models were based on delay differential equations
(DDEs) when focusing on understanding the overall
system dynamics with respect to the length of the delays
in between molecular events, such as that from clock
gene transcription to inhibition. However, those DDE-
based models do not investigate the precise chemical
reactions responsible for the delays so that models
based on ordinary differential equations (ODEs)
were developed that further represent the molecular
events of clock gene transcription, translation, post-
translational regulation, and degradation. Indeed,
those equations represent the variations over time of
intracellular mRNA or protein amounts explicitly com-
puting the reaction rates of molecule interactions, pro-
duction, transport, post-translational modifications,
and/or degradation. ODE-based models and their com-
parisonwith experimental data in normal and knockout
cell lines constitute a critical tool to investigate the
structure of the clock, the involvement of particular
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genes, and the effect on the clock of specific gene
mutations (De Maria et al., 2011).
The cellular clock generates in turn circadian
rhythms in intracellular levels of many mRNAs and
proteins by acting on either gene transcription, trans-
lation, post-translational regulation, or degradation.
Although the molecular details of the clock control on
those processes and their relative importance are
known for certain genes (see The Circadian Timing
System and Its Multilevel Intersubject Variabilities),
more investigations are still needed for critical genes
involved in drug PK-PD, and ODE-based models can in
this study help generate experimentally testable hy-
potheses. For instance, topoisomerase 1 (TOP1) is an
enzyme that relaxes supercoiled DNA and thus partic-
ipates in important molecular processes along the cell
cycle. TOP1 is also the target enzyme of the anticancer
drug irinotecan, whose inhibition results inDNA breaks
and cellular apoptosis. TOP1 mRNA and cytoplasmic
protein levels displayed circadian rhythms in synchro-
nized cell cultures of a human colorectal cancermodel at
confluence (Dulong et al., 2015). Although it has been
shown that the protein dimer CLOCK-BMAL1 pro-
motes TOP1 transcription, the circadian regulation of
TOP1 expression remains still mostly unknown. The
model of the molecular clock by Leloup and Goldbeter
(2003) was supplemented to incorporate Top1 mRNA
and protein dynamics, including the control by CLOCK-
BMAL1. It was calibrated to experimental data on
Bmal1, Per2, and Top1mRNA levels and protein levels,
and concluded that TOP1 protein degradation had to be
under circadian control for the model to match the data
(Hope and Ballesta, 2015). This hypothesis is plausible
as TOP1 is degraded by the proteasome after ubiquiti-
nation, both processes being under the control of the
circadian clock (Pommier, 2006). A full understanding
of the molecular mechanisms involved in the control of
Top1 expression would allow for a reliable prediction of
the gene circadian rhythm according to the clock phase,
hence of cell-type–specific irinotecan chronotoxicity.
b. The molecular clock and cell cycle as a coupled
system. A number of genes controlling the key steps of
initiation, progression, and checkpoint functions of the
cell cycle clock have been identified as being clock-
controlled (Table 1). The circadian clock regulates the
cell cycle by transcriptional control or direct protein–
protein interactions (Fig. 4), including intracellular
signaling (Matsu-Ura et al., 2016). For instance, in
G1, the cyclin-dependent kinase inhibitor P21 is tran-
scriptionally regulated by clock genes REV-ERBa and
RORa/g (Grechez-Cassiau et al., 2008), whereas, at the
G1/S transition, the transcription and RNA splicing
encoding gene NONO regulates the p16-Ink4A check-
point gene in a PER-dependent fashion (Kowalska et al.,
2013). Transcription of theWEE1 kinase (G2/M transi-
tion) is tightly controlled by the CLOCK:BMAL1 dimer
(Matsuo et al., 2003). At the post-translational level,
CRY modulates check (CHK)1/ataxia telangiectasia
and Rad3 related (G1/S transition checkpoint) by
interacting with Timeless in a time-of-day–dependent
manner. PER and Timeless also regulate the G2/M
transition via interactions with CHK2-ATM (Unsal-
Kaçmaz et al., 2005; Kondratov and Antoch, 2007;
Yang et al., 2010; Kang and Leem, 2014). Other clock-
controlled cell cycle regulators include known onco-
genes (c-MYC, MDM2, and b-catenin), cyclins (cyclin
D1, B, and A), and TP53 (Gotoh et al., 2016; Huber et al.,
2016). In particular, c-MYC, which plays a key role in
G1 cell cycle initiation as well as cell growth and death,
is directly transcriptionally regulated by BMAL1/
CLOCK and BMAL1/NPAS2 via the two E-boxes in its
P1 promoter. In contrast, deregulated expression of
c-MYC disrupts the molecular clock in vitro by directly
inducing REV-ERBa to dampen expression and oscilla-
tion of BMAL1 (Altman et al., 2015). Many key cell cycle
regulators, such as cyclin-dependent kinase 4, integrin
subunit a6, Wingless-type mouse mammary tumor
virus integration site family, member 3, LIMHomeobox
2, transcription factor 4, Sex determining region Y box,
SMAD7, and YB-1, are also directly clock-regulated (Fu
and Kettner, 2013; Pagano et al., 2017).
It is reasonable to hypothesize that these regulatory
links constitute the molecular basis for a tight coupling
between the circadian clock and cell cycle networks that
would enable these two oscillators to synchronize and
thus coordinate the cellular processes that they control.
However, it is very difficult to see how to decipher the
dynamic functionality of these molecular interactions
TABLE 1
Cell cycle components regulated by the mammalian circadian clock
Clock Regulators Cell Cycle Targets Mechanism Cell Cycle Event Reference
CLOCK:BMAL1 WEE1 Transcription G2/M Matsuo et al., 2003
REV-ERBa P21 Transcription G1 Grechez-Cassiau et al., 2008
NONO P16/INK4 PPI G1 Kowalska et al., 2013
DEC1 cMYC Transcription G1 Sun and Taneja, 2000
PER1 ATM, CHECK2 PPI DNA damage Gery et al., 2006
PER2 TP53 PPI DNA damage Gotoh et al., 2014
CRY2/TIMELESS ATR, CHECK1 PPI DNA damage Unsal-Kaçmaz et al., 2005
CSNK1D WEE1 Phos G/2M Penas et al., 2014
CSNK1E CDC25 Phos G2/M Piao et al., 2011
Phos, phosphorylation; PPI, protein–protein interaction.
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using classic biochemical and genetics approaches
alone, and the need formodeling and single-cell imaging
is obvious.
One-to-one phase locking of oscillators is a well-
known dynamical phenomenon in which two coupled
oscillators have a fixed relative phase and thus oscillate
with a common frequency (Guckenheimer and Holmes,
1983). A necessary condition for two oscillators to lock in
this way is for their natural frequencies, when
uncoupled, to be close and for them to be coupled
strongly enough. Therefore, it is reasonable to expect
that functional links as above should lead to 1:1 phase
locking of the clock and cell cycle when their uncoupled
periods are similar. Indeed, in theoretical studies, such
phase locking has been shown for mechanistically
detailed mathematical and automaton models of the
mammalian systems (Zamborszky et al., 2007; Altinok
et al., 2011; Gérard and Goldbeter, 2012). This has
recently been investigated by quantifying the dynamics
of the two oscillators in real time, in single live
mammalian cells (Bieler et al., 2014; Feillet et al.,
2014). Both studies used the circadian clock reporter
REV-ERBa::VENUS (Nagoshi et al., 2004). For cell
cycle, Bieler et al. (2014) scored timing of division,
whereas Feillet et al. (2014) added the fluorescent
ubiquitination-based cell cycle indicator cell cycle re-
porter system (Sakaue-Sawano et al., 2008) probing cell
cycle progression. These fluorescent markers were used
to quantitatively determine the properties of each
oscillator in single NIH3T3 mouse fibroblasts. Time
lapse imaging combined with extensive statistical anal-
ysis and modeling exposed the dynamical properties of
these two biologic oscillators.
The results depended upon whether the cells were
synchronized using a 2-hour treatment with dexameth-
asone or were left unsynchronized. When neither clock
nor cell cycle was synchronized by external cues, the
cells appear robustly coupled with a 1:1 ratio between
their respective periods over a wide range of observed
periods (18–27 hours). A clear shortening of the circa-
dian period occurred in dividing cells compared with
nondividing cells, thus revealing an influence of cell
cycle on the clock.Mathematical analysis and stochastic
modeling unambiguously showed that phase locking
rather than gating governs the interaction in NIH3T3
cells. Thus, the phases of the clock and cell cycle are
coordinated all the way around the circadian cycle.
Changing cell cycle duration impacted on circadian
cycles, but 1:1 locking was resilient to such changes
(Bieler et al., 2014; Feillet et al., 2014). Additionally,
inhibition of the cell cycle at the G1/S or G2/M transi-
tions lengthened circadian intervals and delayed di-
vision phase. Bieler et al. (2014) looked at the reverse
interaction by changing circadian period. This did not
affect cell cycle length, but advanced division with
respect to circadian phase. The authors thus proposed
a unidirectional coupling from the cell cycle to the
circadian clock (Bieler et al., 2014), but this experi-
mental result is also compatible with bidirectional
coupling.
Fig. 4. Molecular pathways of the circadian clock control on the cell cycle machinery (adapted from Gérard and Goldbeter, 2012). Several molecular
processes along the cell cycle are regulated by the clock. At the early G1 phase, the BMAL1/CLOCK heterodimer downregulates Myc transcription to
prevent its overexpression. In response to double-strand DNA damage, PER1 directly interacts with ataxia telangiectasia mutated and CHK2 to
control G1 checkpoint. DNA damage induced by g-radiation activates ataxia telangiectasia mutated/CHK2-mediated G1/S and G2/M checkpoints via
p53 and p21. DNA damage induced by UV radiation leads to activation of ATR/CHK1-mediated intra-S checkpoint. In S phase, CRY2/TIM complex
directly interacts with ATR/CHK1. In the G2 phase, PER-mediated ataxia telangiectasia mutated/CHK2/p53 signaling in response to DNA double-
strand breaks leads to activation of G2/M checkpoint. BMAL1/CLOCK-activated Wee1 expression leads to activation of G2/M checkpoint.
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When, in contrast, the cells had a 2-hour treatment
with dexamethasone, which resets the circadian clock,
two distinct dynamical behaviors were observed (Feillet
et al., 2014). Whereas one subpopulation kept a 1:1
phase locking, outside this the ratio of cell cycle and
clock periods was different and often in a ratio p:q (i.e.,
p cell cycles for q clock cycles), where p and q are small
integers. For example, when the cells were grown in rich
20% fetal bovine serum (FBS) culture medium, p:q was
3:2, and, when this was reduced to 10% FBS, p:q = 5:4
was observed. This is compatible with the way that
increased FBS was observed to speed up the oscilla-
tions. Moreover, when projecting the timing of mitosis
across the whole experiment, a clear clustering of cell
division was observed, suggesting that the cell cycle was
synchronized by physiologic cues via the circadian clock,
again supporting bidirectional coupling. This behavior
is entirely in accordance with what would be predicted
from the mathematical theory for coupled deterministic
oscillators.
Introduced in Mori et al. (1996), gating is defined as
clock-based control of cell division which is allowed at
certain clock phases and forbidden during others, thus
creating proliferation checkpoints. The gating model
differs from the phase-locking model in which, in noise-
free systems (and approximately in stochastic systems),
the two oscillators are synchronized over the whole
period so that observing the phase of one system
provides information on the phase of the other. The
above studies suggest the rejection of the concept of
gating of the cell cycle by the clock in mammalian cells
in favor of phase locking and indeed in the movies of
Feillet et al. (2014), showing how the cell cycle and clock
phases progress in single cells; there is no evidence of
cells queuing to get through a gate. In the end, it seems
that the cell cycle is capable of impacting on the
circadian clock and vice versa, the dominant influence
being dependent on the environment of the cell. Phase
locking is a characteristic phenomenon of coupled
oscillators and is likely to be a much-used mechanism
used to function coordinate different cellular oscillators.
A major impact of clock and cell cycle coupling on cell
physiology resides in timed mitoses (e.g., about one-
sixth of human epidermal cells divide daily) in that local
intracellular clock/cell cycle coupling most likely gov-
erns rhythmic mitosis at the cellular and tissue levels,
whereas systemic circadian cues are required to co-
ordinate cell divisions in the whole organism. An
important example of clock control of the cell cycle that
addresses this hypothesis from a different angle is
provided by the discovery that different populations of
epidermal stem cells express clock genes in opposite
phases. This results in a differential propensity for
activation, and it has been suggested that this hetero-
geneity may have evolved to allow the cells both to self-
renew, thus replenishing their reserve in the niche, and
to keep a ready-to-go population that can respond to the
signals that trigger differentiation. Specific disruption
of the circadian clock in these cells led to premature
epidermal ageing, which confirms that local coupling is
necessary to ensure tissue integrity (Janich et al., 2011).
The interplay between the clock and cell cycle is of
primary relevance to cancer because disordered circa-
dian function has been implicated in the pathogenesis
of cancer, and a deregulated cell cycle is a hallmark
of cancer cells (Lévi and Schibler, 2007; Hanahan
and Weinberg, 2011). Among the hallmarks of cancer,
genome instability and mutations in cell cycle genes are
a recurring enabling factor (Hanahan and Weinberg,
2011), with mutations in cyclin, cyclin-dependent kinase,
or cyclin-dependent kinase inhibitor genes found
in 90% of human cancers (Bonelli et al., 2014). In
contrast, evidence is increasing that cancer cells also
display a deregulation of the circadian clockwork,
which may promote abnormal proliferation (Fu and
Kettner, 2013).
2. Cell Population Dynamics. The final objective of
systems chronopharmacology lays in the prediction of
the drug effect on a whole tissue rather than at the level
of a single cell. Hence, several mathematical ap-
proaches were undertaken to model cell proliferation
and its circadian control at a cell population scale, and
efforts have been made to link those models to the
single-cell representations as in a multiscale pipeline.
a. Age-structured partial differential equation and
DDE models. Models of the dynamics of a cell pop-
ulation were designed based on partial differential
equations (PDEs) incorporating both time and the age
of the cells in their current cell cycle phase as structure
variables (Billy et al., 2013, 2014; El Cheikh et al.,
2014). Conversely to classic ODE-based cell population
models, those equations present the advantage of
imposing a minimum duration for cell cycle phases,
which is an important physiologic feature to predict cell
dynamics. Intercell variability in cell cycle phase dura-
tions followed a g distribution in unsynchronized
NIH3T3 in vitro experiments, which can be imple-
mented in those models by choosing the corresponding
phase transition functions (Billy et al., 2014). Those
PDE models can also take into account the circadian
control of both cell death pathways—though oscillating
death rates—and of cell cycle phase transition and
checkpoints—through transition functions displaying
24-hour rhythms. Starting from these PDE-based mod-
els and assuming no intercell variations in phase
durations, DDEs can also be derived to model circadian-
controlled cell proliferation (Bernard et al., 2010). In
this case, the delays correspond to the common length
of the cell cycle phases.
The main advantage of those types of models re-
sides in the small number of parameters to estimate
from data and the possibility to represent long-
term behaviors and further derive theoretical conclu-
sions. Recently, El Cheikh et al. (2014) also combined
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an ODE-based model representing the molecular inter-
connections between the circadian clock and the cell
cycle to a PDE-based cell population model. They
showed that the clock/cell cycle coupling increases the
growth rate of cell populations for autonomous cell cycle
length around 24 hours and above 48 hours. Moreover,
they predicted that CRY1/CRY2 mutations decreased
the cell population growth rate for all periods of the cell
cycle, which was in agreement with lower liver re-
generation potency experimentally found in CRY mu-
tant mice. The loss of functional PER2 was predicted to
lead to an enhanced proliferation, which is consistent
with PER2 being reported as a tumor suppressor gene.
Finally, BMAL1 knockout also increased the growth
rate for cell cycle length smaller than 21 hours and
decreased it elsewhere.
b. Agent-based models. An alternative approach to
predict cell population dynamics consists in represent-
ing each cell individually although so-called agent-
based models or cellular automaton. A combination of
logical rules and intracellular ODE model simulations
takes as input cues the cell spatial and chemical
environment to ultimately define its behavior. The cell
population dynamics is thus computed by assessing
those rules for each considered cell, and intercell
stochastic variability is often assumed in particular in
gene expression. This type of modeling presents the
advantage of being very flexible and can thus faithfully
represent the biology. However, its computational cost
can be very high because it proportionally increases
with the number of cells considered. As an example,
Nguyen et al. (2013) developed such a model to repre-
sent the circadian dynamics of inflammatory response
after endotoxin administration in vivo, taking into
account the cell-to-cell communication and intercell
stochasticity. In silico experiments suggested that cell-
to-cell synchronization in the leukocyte population was
enhanced after endotoxin exposure.
B. Multiscale Physiologically-Based ChronoPK-PD
Modeling toward Therapies Personalization
Modeling of healthy and diseased tissues in the
absence of drugs, as presented above, needs to be
supplemented with PK-PD models to allow for pharma-
cotherapy optimization. Although classic compartment-
based PK-PDmodeling has a strong descriptive value in
particular regarding interpatient differences, their pre-
dictive power is weak so that new mathematical
methods are needed. Physiologically-based models rep-
resenting the molecular mechanisms involved in drug
chronoPK-PD have gradually appeared as critical tools
to predict drug efficacy and side effects.
1. What Is Physiologically-Based PK-PD Modeling?
Drug toxicity and efficacy are ultimately determined by
the gene and protein networks involved in cellular,
organ, and whole-body PK-PD. Hence, modeling the
dynamics of the key molecular events constitutes a
rational basis for treatment optimization. Thus,
physiologically-based pharmacology modeling, first in-
troduced by Rowland (1984), has rapidly developed over
the past years, resulting in the implementation by
pharmaceutical industries of dedicated clinically-
focused software such as PKSim (Bayer) and Simcyp
(Certara). Physiologically-based modeling consists in
the quantitative representation of the molecular path-
ways involved in drug pharmacology and efficacy. These
models are based on ODEs and represent in each
considered physical compartment the following: 1) the
concentrations of the parent drug and its metabolites
over time, resulting from biochemical events such as
bioactivation, detoxification, passive diffusion, or active
transport; 2) the drug activity on the cells, such as
pathway activation, DNA damage leading to DNA
repair, cell cycle arrest, and/or cell death. Hence, all
model variables and parameters do have a physical or
biochemical significance, which allows for direct com-
parison with corresponding experimental or clinical
measurements.
2. Multiscale Approach To Design Physiologically-
Based Patient Model. The outcome of pharmacother-
apies has long been known to depend upon both
patient- and disease-specific genetic, epigenetic, or
behavioral specificities. Thus, treatment personaliza-
tion is required to ensure optimal health manage-
ment. The fact that physiologically-based models
integrate the molecular details of drug PK-PD allows
one to explicitly integrate patient- or disease-specific
molecular and lifestyle information. However, the
temporal and spatial organizations of such complex
physiology cannot be exhaustively measured in indi-
vidual patients, due to the invasive and sometimes
ethically questionable nature of the required clinical
sampling procedures. Indeed, physiologic models in-
volve a large number of kinetic parameters, which is
often considered as the main drawback of the ap-
proach. Such limitations can be palliated by the use of
a multiscale systems medicine approach, which inte-
grates experimental results obtained in cell cultures,
laboratory animals, healthy human subjects, and
patient populations (Fig. 5). Indeed, because the
models are based on the physiology, submodel structure
and parameter values are conserved and can be either
directly inferred or scaled on physiologic basis from one
scale to another. Such pipeline thus allows for the design
of a patient-specific PK-PDmodel that provides the basis
for chronotherapeutics personalization.
Multiscale chronoPK-PD approaches start with
in vitro investigations either in solutions or in cell
culture to design and calibrate a detailed molecular
chronoPK-PD model at the cellular level. Then mouse
studies serve as a basis to design the drug-specific
structure of the whole-body PK-PD model, which incor-
porates the cellular model to represent each considered
organ. Next, a model for an average patient can be
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obtained by keeping the structure of the mouse model
and resizing the parameters for humans using physio-
logic literature information combined to clinical data-
sets in patient populations. More precisely, model
parameters can be scaled from mouse to human as
follows: 1) organ volumes are inferred from literature
values for each species according to age and sex (Davies
and Morris, 1993; Marino, 2012); 2) intracellular re-
action rates are kept unchanged from the preclinical
models; 3) protein activities are proportionally scaled
according to interspecies in vitro studies (Davies and
Morris, 1993; Satoh and Hosokawa, 1998; Maier-
Salamon et al., 2011); 4) blood-to-organ transport and
drug clearance parameters can be scaled using physio-
logic information such as volumes or blood flows,
although more work is needed in this area to develop
a validated scaling method. Sensitivity analyses are
then performed to determine the relative importance of
model parameters and select the most influential; ones
that will be modified for obtaining a patient-specific
model. Hence, this analysis may also guide the search of
relevant circadian or pharmacological biomarkers to be
measured in patients. The human model is then
partially recalibrated using individual patient datasets
and further serves in optimization procedures to com-
pute personalized administration schemes.
As an example, we detail in this work the design of a
physiologically-based model of temozolomide (TMZ) brain
disposition through a multiscale pipeline integrating PK
studies in buffer solutions, cell culture, mice, and patients
(Ballesta et al., 2014). As TMZ PK is pH-dependent, it
was first studied in buffer solutions. TMZ conversion
into 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide
(MTIC) and MTIC subsequent fragmentation into
4-amino-5-imidazole-carboxamide (AIC) and a meth-
yldiazonium cation—the highly-reactive active species
responsible for DNA adducts—were represented in a
first mathematical model (three variables, four param-
eters), which was calibrated to experimental results on
TMZ, MTIC, and AIC levels in solutions at different
pHs. Next, TMZ cellular PK was represented through
two compartments representing the extra- and in-
tracellular medium, both incorporating the model of
the buffer solution studies. Thus, the only parameters
left to estimate were those associated to drug cellular
uptake and efflux. They were estimated from TMZ,
MTIC, and AIC concentrations measured in U87
glioma cells and corresponding extracellular medium.
Regarding TMZ PD, DNA adducts formation by the
active cation was represented through a linear kinetics
involving one parameter estimated from literature
data. To account for interlaboratory differences and
to allow for a better fit of the cell culture data, a 50%
deviation was allowed for the four parameters of the
solution study whose data were obtained from a
different research group. Next, a model of TMZ brain
disposition in mice was developed incorporating the
cellular model. The extra- and intracellular compart-
ments of the latter now correspond to the interstitial
fluid and tumor cells within the brain tumor. The
normal brain was represented in the samemanner and
served as a control for the cancer compartments. A
compartment for the blood was also added to account
for systemic drug administration, and TMZ blood PK
was modeled by a forcing function independently fitted
to TMZ plasma PK in normal nude mice. Tumor cell
membrane transport parameters were scaled from the
in vitro investigation using volumes, whereas all in-
tracellular parameters were kept unchanged. The six
remaining parameters for 1) normal brain cell mem-
brane transport and 2) transport between the blood
compartment and the interstitial fluids were esti-
mated from PK data in normal and U87 tumor-
bearing nude mice. Finally, the human model was
obtained by keeping the mouse model structure and
intracellular parameter estimates and scaling all
transport parameters proportionally to volumes. How-
ever, a comparison of this naive model to TMZ concen-
tration measurements in the interstitial fluid of cancer
patients revealed that the model overestimated drug
concentrations by up to fivefold, thus advocating for a
refined scaling method. Moreover, this model of TMZ
PK can be extended to account for the circadian
rhythms of drug transport and plasma protein binding.
3. Optimization Procedures toward the Design of
Personalized Pharmacotherapies. For a given drug,
a patient-specific physiologically-based chronoPK-PD
model is a critical tool, as it can theoretically predict
the efficacy and toxicities of any administration sched-
ules in the individual patient. Once it is designed and
validated, the next step consists in utilizing it in
optimization procedures to compute patient-tailored
chronotherapies. The chronotherapeutics optimization
problem can be formulated as an objective function (e.g.,
Fig. 5. A systems medicine approach for personalized chronotherapeu-
tics. Individual patient data—such as measurements of circadian
biomarkers, gene polymorphism, patient general characteristics, or
disease history—are input into the systems medicine algorithm that
computes personalized chrono-infusion schemes. The algorithm is de-
veloped through a multiscale pipeline integrating mathematical and
experimental investigations in cell culture, in laboratory animals, and in
patient populations. Results in multiple cell lines, animal strains, and
patient subgroups allow for the reliable design of the personalization
framework.
176 Ballesta et al.
maximizing efficacy on cancer cells) subject to con-
straints (e.g., tolerability thresholds). Then optimi-
zation methods can be implemented to find the
parameters of the single-agent administration timing
(dose, duration, circadian time, ...) that achieve the
optimal value of the objective function (Basdevant et al.,
2005; Ballesta and Clairambault, 2014). This method-
ology can also serve to optimize the combination of the
single agent with molecules targeted to proteins repre-
sented in the chronoPK-PDmodel (Ballesta et al., 2013).
The targeted agent is represented in the model as a
modification of the corresponding intracellular or sys-
temic protein levels. Those parameters are then in-
cluded in the optimization procedures that compute the
optimal administration scheme of the single agent
together with the optimal protein levels. This method
only represents the PD of targetedmolecules and aim at
drug selection. Complete optimization requires repre-
senting the cellular and whole-body chronoPK of the
targeted molecules to predict proper timing.
Optimal control theory and a descent algorithm have
been applied to improve oxaliplatin chronomodulated
delivery schedule along these lines (Basdevant et al.,
2005). In this study, a simplified model of oxaliplatin
PK-PD was developed based on both drug jejunal
chronotoxicity and antitumor chronoefficacy. When
aiming at eradicating the tumor under a constraint of
tolerability, the theoretically optimal drug administra-
tion was a nontrivial chronomodulated drug infusion
flow whose shape was critically determined by the
numerical value of the toxicity threshold. Moreover,
constant rate infusions always achieve worse therapeu-
tic outcomes than optimized time-scheduled regimens
in these models.
An alternative methodology consists in solving the
optimization problem through numerical algorithms.
An in vitro proof of concept of this approachwas recently
provided in NIH3T3 mouse fibroblasts either normal or
modified to overexpress the oncogene SRC, the latter
being considered as the cancer cells and the former as
the healthy cells. In this experimental setting, the
exposure of both cell populations to the same doses of
various anticancer drugs combined or not to SRC-
targeted molecules resulted in a moderate efficacy in
transformed cells and an unacceptable cytotoxicity in
normal fibroblasts. Physiologically-based modeling in-
formed by protein level quantification in both cell types
was used in optimization procedures, which allowed for
the identification of nonintuitive anticancer drug com-
binations and scheduling inducing apoptosis in cells
mutated for the oncogene SRC, but not in normal cells.
The optimal combination chemotherapies relied on the
administration of a cytotoxic drug and a SRC-targeted
molecule combined to an inhibitor of the proapoptotic
protein BAX, which was surprisingly more expressed in
transformed cells compared with normal ones. Decreas-
ing BAX level by the same quantity in both cell
populations allowed for sheltering of healthy cells that
could not trigger apoptosis anymore in the absence of
BAX, whereas cancer cells were still drug sensitive
because their initial BAX level was higher. The same
optimization methods were further used for the optimi-
zation of irinotecan chrono-exposure in cell culture,
described in this work after (Ballesta et al., 2011).
V. Cancer as a Driver for
Systems Chronotherapeutics
Proper timing of chemotherapies is particularly
relevant for anticancer drugs, which are often adminis-
tered near their maximum-tolerated dose, thus induc-
ing adverse events, whose severity could be minimized
by targeting specific times of day. Similarly, radia-
tion therapy’s therapeutic index could be improved by
optimizing timing of administration (Chan et al., 2016,
2017a,b). Moreover, tumor tissues usually display a
disrupted circadian organization—at least at an ad-
vanced stage (Kettner et al., 2014). The difference in
circadian synchronization between healthy and cancer
tissues can then be exploited in treatment timing
to specifically shield healthy cells while targeting
cancer cells.
A. Preclinical and Clinical Cancer Chronotherapeutics
1. Preclinical Drug Chronotolerance and Chronoefficacy.
Preclinical investigations performed in mice or in rats
have demonstrated that circadian timing largely mod-
ifies the toxicity of nearly 50 anticancer drugs, including
cytostatics, cytokines, and targeted molecules (Lévi
et al., 2010). Rodent survival and bodyweight loss varied
from 2- to 10-fold, according to circadian timing of the
samedrug dose. The circadian times of least toxicitywere
staggered along the 24-hour span and differed for
molecules in the same pharmacological class advocating
for systems molecular chronopharmacology to predict
optimal timing (Lévi et al., 2010). The chronotoxicity
rhythms arose from the circadian control of PK-PD and
cytotoxicity. First, timing-dependent blood and/or tissue
PK were observed in rodents for 17 anticancer drugs.
Such chronoPK rhythms not always coincided with
chronotoxicity patterns, thus attesting to the existence
of circadian rhythms in cellular drug target, DNA repair,
cell cycle, and/or cell death pathways (Lévi et al., 2010;
Sancar et al., 2015).
Next, 28 anticancer molecules presented time de-
pendencies in their antitumor efficacy of various am-
plitudes as measured by survival of tumor-bearing mice
and tumor growth rate (Lévi et al., 2010). The chro-
noefficacy rhythms may at least partly originate from
the circadian control of drug metabolism and distribu-
tion at the whole-body level, which influences tumor
drug concentrations. In contrast, in vitro studies have
shown that some cancer cell lines, such as human breast
cancer MCF-7, have lost circadian rhythmicity in clock
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gene transcription (Xiang et al., 2012), whereas others
such as human colon cancer Caco-2 at confluence have
retained coordinated circadian expression (Dulong
et al., 2015). However, most studies in vivo have shown
the lack of consistent 24-hour patterns in experimental
cancer tissues, especially for poorly differentiated car-
cinomas (Lévi et al., 2010).
Recent mouse investigations have highlighted large
sex- and strain-related differences in drug chronophar-
macology and chronotoxicities. The mRNA circadian
expressions of genes involved in the anticancer drug
irinotecan chronopharmacology, including CES2 (bio-
activation), UGT1A1 (detoxification), ABCC2 (trans-
port), and TOP1 (target enzyme), as well as irinotecan
pharmacokinetics, differed according to sex and strain
(Ahowesso et al., 2010; Okyar et al., 2011). Next, a large
prospective investigation involved eight mouse cate-
gories, including two with clock gene PER2 mutation,
and revealed an 8-hour difference in the optimal timing
of irinotecan. Twenty-seven circadian time series of
mRNA gene expressions in the liver and in the colon
mucosa were analyzed, although sparse linear discrim-
inant analysis and the circadian transcriptional pat-
terns of REV-ERBa and BMAL1 best discriminated
between the chronotoxicity classes. Further analysis
through maximum a posteriori Bayesian inference
allowed the design of a linear model of REV-ERBa
and BMAL1 circadian mRNA expressions, which accu-
rately predicted the irinotecan chronotoxicity pattern
(Li et al., 2013). Overall, these results emphasized the
importance of mouse sex and strain in chronotherapeu-
tics studies, together with the relevance of tracking
circadian clock biomarkers for predicting optimal tim-
ing in different individuals, despite exposure to the
same environmental synchronizer.
2. Current Challenges of Cancer Chronotherapeutics
in the Clinics. Clinical investigations, including ran-
domized Phase III trials, have tested the timing effects
of several anticancer chemotherapies. Proper circa-
dian timing improved treatment outcome achieving
an up-to-fivefold decrease in drug toxicity and nearly
twofold increase in antitumor efficacy compared with
noncircadian-based administration of the same drug
doses (Lévi et al., 2010; Dallmann et al., 2016). How-
ever, recent clinical studies have demonstrated that the
patient’s sex and genetic background have a large
influence on the optimal timing of drug administration
(Giacchetti et al., 2012; Roche et al., 2014). Nowadays, a
unique chronotherapy infusion scheme directly inferred
from mouse studies is administered to all patients,
which results in a large interpatient variability in
treatment outcome. In the case of metastatic colorectal
cancer (mCRC), the fixed three-drug chronotherapy
schedule ChronoFLO4 increased the overall survival
of male patients compared with constant or other
conventional administration method of the same drug
doses, but decreased that of female patients according to
a meta-analysis of three randomized international
trials (Giacchetti et al., 2012). Interestingly, metastatic
adenocarcinoma patients who did not tolerate an ad-
ministration of 5-FU at 3:00 to 4:00 AM benefited from
an infusion of the same drug at 9:00 to 10:00 PM
(Bjarnason et al., 1993). Overall, these results suggest
that personalized chronotherapy, designed through
dedicated systems medicine approaches, is likely to
increase patient’s response to treatment.
Although most chemotherapies are administered di-
rectly into the central blood circulation, hepatic admin-
istration of antitumor drugs to colorectal cancer (CRC)
patients with liver metastasis have now appeared as a
very promising strategy. The European phase II clinical
trial OPTILIV successfully tested in CRC patients the
hepatic artery infusion of the anticancer drugs 5-FU,
oxaliplatin, and irinotecan, combined to the targeted
molecule cetuximab (Lévi et al., 2016). Although pa-
tient’s survival of this trial exceeded by far the usual
survival in similar patient populations, plasma PK
measurements revealed that the chronomodulated ad-
ministration schemes used for oxaliplatin and irinote-
can resulted in systemic exposure outside the targeted
therapeutic time windows in several patients (Fig. 6)
(Lévi et al., 2017). Hence, systems approaches are
required to optimize hepatic administration schedules.
Moreover, large interpatient differences were demon-
strated in the plasma PK profile of all four drugs, which
correlated with toxicity severity for oxaliplatin, thus
advocating for personalized hepatic administration
schedules to be designed and tested.
B. Anticancer Systems Chronopharmacology
Personalizing cancer chronotherapeutics requires an
extensive molecular knowledge of anticancer drug
chronopharmacology and chronotoxicity both in healthy
and tumor tissues. Indeed, the understanding of molec-
ular mechanisms governing drug PK-PD, cell cycle, cell
death, and their circadian control allows for accurate
predictions of drug chronotoxicity according to tumor
mutations and patient-specific gene polymorphisms
and chronotypes. Such complex phenomena may highly
benefit frommathematical modeling and systems phar-
macology approaches that guide experimental design,
and further allow for predictions from preclinical stud-
ies of most influential genes as potential circadian
biomarkers for the clinics. We in this work review
systems chronopharmacology studies of irinotecan,
5-FU, and oxaliplatin, the three cytotoxic drugs consti-
tuting the gold standard treatment of colorectal cancer
(CRC), the third most common malignancy worldwide
(Siegel et al., 2016).
1. Irinotecan. Irinotecan is a topoisomerase inhibi-
tor active against colorectal and gastrointestinal malig-
nancies, yet with dose-limiting intestinal and hematologic
toxicities. Irinotecan PK-PD, toxicities, and efficacy dis-
played circadian rhythms in synchronized cell culture, in
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mice and in cancer patients (Ballesta et al., 2012; Dulong
et al., 2015). Irinotecan is usually administered to cancer
patients mostly in combination with other cytotoxic drugs
and/or targeted molecules (Lévi et al., 2010; Sasine et al.,
2010). However, there is a critical need for a rational
design of irinotecan-based chronomodulated drug combi-
nations according to individual patient data (Campbell
et al., 2017). To this end, in vitro and rodent systems
chronopharmacology studies investigated the molecular
determinants of irinotecan chronotoxicity and chronoeffi-
cacy (Fig. 7).
a. Irinotecan systems chronopharmacology in cell
culture. Recent in vitro investigations have character-
ized irinotecan chronopharmacology at the molecular
scale in human colorectal adenocarcinoma Caco-2 cells
(Ballesta et al., 2011; Dulong et al., 2015). Experimental
design was guided by an ODE-based physiologic PK-PD
model that considered the following: 1) irinotecan
passive diffusion through the cell membrane and bio-
activation into SN38 through carboxylesterase; 2) SN38
detoxification into SN38G through UGT1As; 3) irinote-
can, SN38, and SN38G efflux outside of the cells by ABC
transporters. Regarding the PD part of themodel, SN38
was assumed to stabilize its target TOP1 on the DNA,
creating reversible complexes that become irrevers-
ible after collision with replication mechanisms. The
amount of irreversible complexes was used as an output
of irinotecan toxicity, as it was highly correlated with
cell death in cell culture (Ballesta et al., 2011). Proteins
involved in irinotecan efflux, bioactivation, detoxifica-
tion, and the drug target TOP1 were assumed to display
circadian rhythms.
In the first study (Ballesta et al., 2011), circadian
variations with a period of 26h50 (S.D. 63minutes) were
found in synchronized Caco-2 cells for the mRNA levels
of the three clock genes REV-ERBa, PER2, BMAL1,
and in that of TOP1, CES2, UGT1A1, and efflux
transporters ABCB1, ABCC1, ABCC2, and ABCG2.
DNA-bound TOP1 protein amount in the presence of
irinotecan also displayed circadian rhythms. The model
parameters were estimated from data, and the best-fit
model closely reproduced the experimental datasets.
Next, the data-calibrated model was used in numeri-
cal optimization procedures to compute theoretically-
optimal exposure schemes for Caco-2 cells (Fig. 8).
Considered schemes consisted of an in vitro exposure
to a given concentration of irinotecan, over 1–27 hours,
starting at a particular CT. Synchronized cells were
considered as healthy ones, and nonsynchronized cells
as cancer ones (Lévi et al., 2010). The optimization
process aimed at maximizing drug efficacy on cancer
cells under the constraint that toxicity in the healthy
cell population remained under a fixed tolerability
threshold. For all considered thresholds, the optimal
Fig. 6. Relationship between hepatic chronomodulated delivery schedules and plasma PK profiles in metastatic cancer patients from the Optiliv trial.
Irinotecan (A–C), Oxaliplatin (D–F), and 5-FU (G–H) were administered according to specified infusion patterns in the hepatic artery of 11 cancer
patients. For irinotecan and oxaliplatin, a significant delay was observed between the administration peak time and the plasma PK curves of both
administered agents and corresponding active metabolite or ultrafiltrate concentration. On the opposite, 5-FU plasma concentration closely followed the
infusion profile for all patients. Large interpatient variability was observed in the plasma PK of all measured quantities [data from Lévi et al. (2017)].
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exposure scheme consisted in administering irinotecan
over 3h 40min to 7h 10min starting between CT 2h
10min and CT 2h 30min which corresponded to 1h
30min to 1h 50min before the nadir of carboxylesterase
activation enzymes. The optimal schemes were not
centered on the nadir of the latter rhythm but rather
extended after it, when efflux transporters and de-
activation enzymes were higher and therefore protected
more efficiently healthy cells. The optimal schemes
induced twice as much DNA damage in cancer cells as
in healthy ones. Of note, the optimal duration did not
exceed, highlighting the need for short exposure dura-
tions to optimally exploit the temporal difference be-
tween healthy and cancer cells.
Irinotecan chronopharmacology was further investi-
gated in a second study in synchronized Caco-2 cells
(Dulong et al., 2015). Consistently with the first study,
large transcription rhythms of period 28 hour 06minute
Fig. 7. Multiscale systems chronopharmacology to personalize irinotecan chronotherapy. An in vitro study of irinotecan chronopharmacology led to the
design of a cellular chronoPK-PD model (A) incorporating multitype experimental data, including the extra- and intracellular concentrations of active
metabolite SN 38 and irinotecan-induced apoptosis after irinotecan exposure at three CTs (B–D) Dulong et al., 2015). This cellular investigation
provided the basis for a mouse study and the development of a whole-body model of irinotecan chronoPK-PD explicitly incorporating the cellular model
in relevant organs (E) (Ballesta et al., 2012). The model was first developed for B6D2F1 male mice in which several chronopharmacology datasets were
available, including plasma and colon chronoPK profiles of SN38 after irinotecan at best and worst time of tolerability (F–G). The next step will consist
in fitting intestinal chronotoxicity data available for the same mouse category (H) (Li et al., 2013). Dots or bars represent experimental results, and
solid lines represent best-fit models.
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(S.D. 1 hour 41 minute) moderated irinotecan bioacti-
vation, detoxification, transport, and target. These
molecular rhythms translated into statistically signifi-
cant changes according to drug timing in irinotecan
pharmacokinetics, in DNA-bound TOP1 amount during
SN38 exposure, and in drug-induced apoptosis. Clock
silencing through siBMAL1 exposure ablated all the
chronopharmacology mechanisms, demonstrating they
originated from the molecular circadian clock. The
PK-PD model developed in the first study was fitted to
these new datasets and achieved a good fit. Parameter
sensitivity analysis performed on the model allowed
to assess the relative importance of pharmacological
proteins with respect to irinotecan chronotoxicity.
They concluded on the dominant role of the activa-
tion enzymes carboxylesterases and the detoxification
Fig. 8. Optimizing irinotecan chronotherapy in Caco-2 cell culture (adapted from Ballesta et al., 2011). (A) Predicted drug cytotoxicity in synchronized
cells with respect to exposure duration and circadian time of beginning of exposure. The cumulative dose was set to 500 mM/h. (B) Optimal exposure
schemes following the strategy of maximizing efficacy in unsynchronized cells considered as cancer cells, under a constraint of maximal allowed toxicity
in synchronized cells, considered as healthy cells. The toxicity threshold was varied (y-axis), and corresponding optimal schemes consisted in
administering the optimal cumulative dose (written in green) over 3h40 to 7h10, starting between CT2 and CT3.
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enzymes UGT1As in the phase and amplitude of the
drug chronotoxicity rhythm.
b. Irinotecan systems chronopharmacology in mice.
As in a multiscale approach, irinotecan chronopharma-
cology was then investigated in several C57BL/6-based
mouse strains, in bothmale and femalemice. Irinotecan
toxicity patterns were assessed through mouse sur-
vival, body weight loss, and intestinal and hematologic
toxicities, and three classes of chronotoxicity were found
(Ahowesso et al., 2010; Li et al., 2013).
To gain a mechanistic understanding of irinotecan
chronopharmacology, a whole-body model of irinotecan
chronoPK-PD was designed, building on the cellular
model from the prior in vitro studies (Ballesta et al.,
2012). It included seven compartments representing the
blood, the liver that plays a critical role in drug metab-
olism, both main toxicity targets—intestine and bone
marrow, the noneliminating tissues, and the tumor to
account for drug efficacy. The intestine was divided into
two compartments, representing intestinal mucosa
cells, and intestinal lumen, respectively. A bidirectional
transport was assumed between the blood and all
organs, except for the transport from the intestinal cells
to the hepatic portal vein, which was represented by a
flow directly toward the liver. The enterohepatic circu-
lation was also modeled by a drug transport from the
liver to the intestinal lumen, which stood for biliary
excretion. Renal and intestinal clearancewere included,
respectively, in the blood and intestinal lumen com-
partments. Model parameters were either inferred from
the in vitro studies or estimated from experimental data
available in the three classes of irinotecan chronotox-
icity (Li et al., 2013). Both PK time–concentration
profiles in blood and tissues after administration at
the best and worst time of tolerability and circadian
expression of pharmacological proteins were integrated
in parameter estimation (Ballesta et al., 2012). Results
showed a good model-to-data fit for male B6D2F1 male
mice. This whole-body chronoPK-PD model is being
extended to further study the molecular determi-
nants of irinotecan chronopharmacology in other mouse
categories.
2. Oxaliplatin. Oxaliplatin is a platinum complex
that is effective against human colorectal cancer. The
main adverse events of the drug include diarrhea,
hematologic suppression, and peripheral sensory neu-
ropathy. Circadian rhythms in oxaliplatin PK, toxic-
ities, and antitumor efficacy have been described in
mice and in cancer patients (Lévi et al., 2010). In
addition, high Bmal1 expression was recently associ-
ated with increased efficacy of oxaliplatin-based che-
motherapy against colorectal cancer (Zeng et al., 2014).
Altinok et al. (2009) used a physiologically-based PK
model coupled to a cellular automaton of the cell cycle to
study oxaliplatin chronotoxicity. The authors modeled
the drug action as an increase in the propensity of
quitting the cell cycle, regardless of the cell current
phase as oxaliplatin cytotoxicity is not cell cycle phase-
specific. A chronoPKmodel was designed accounting for
oxaliplatin transport between plasma and cells, drug
binding to plasma proteins, and intracellular detoxifi-
cation, although reduced reduced glutathione. Both
plasma protein and reduced glutathione amounts were
assumed to display circadian variations, and their
respective acrophases were set to 4:00 PM and 12:00
PM according to clinical data and extrapolated results
frommouse investigations. Oxaliplatin cytotoxicity was
predicted to be more pronounced when delivered at 4:00
AM rather than at 4:00 PM as a consequence of lower
protein binding and detoxification. This theoretical
result aligned with clinical findings on oxaliplatin
chronotoxicity (Lévi et al., 2010).
Another work undertook a different mathematical
approach to study time-scheduled regimens of oxalipla-
tin administered to mice bearing Glasgow Osteosar-
coma (Basdevant et al., 2005). The model represented
oxaliplatin toxicity in two cell populations: 1) a popula-
tion of tumor cells and 2) a population of fast renewing
healthy cells in the jejunal mucosa. First-order phar-
macokinetics was assumed for total platinum concen-
tration in the plasma, the jejunal mucosa, and the
tumor compartments. The healthy cell population was
modeled by two ordinary differential equations repre-
senting mature and young cells, the latter ones being
sensitive to oxaliplatin. The tumor dynamics was
assumed to follow a Gompertz law modified to account
for oxaliplatin toxicity. Circadian rhythms were as-
sumed for oxaliplatin cytotoxicity against young entero-
cytes and tumor cells. The model was partly calibrated
to literature data and used in optimal control computa-
tions. Therapeutic strategy consisted in maximizing
drug effect on cancer cells under the constraints of
healthy cells remaining above a given threshold repre-
senting acceptable toxicity. Optimal infusion profiles
were not superimposable onto the 24-hour cosine wave
of oxaliplatin delivery currently used in the clinics. Yet,
the authors concluded that more work was needed on
parameter estimation and model validation before
taking these results to the clinics.
3. 5-Fluorouracil. The 5-FU is an antimetabolite
drug that has been administered to colorectal cancer
patients since 1957 and still remains the cornerstone of
current therapeutic strategies against intestinal malig-
nancies. Large circadian variations modulated 5-FU
tolerance and efficacy both in mice and in cancer
patients (Lévi et al., 2010).
The 5-FU chronotolerance was studied through an
agent-based model representing healthy and tumor
human cells (Altinok et al., 2009). Cell cycle phase
duration and circadian timing were inferred from the
literature for healthy cells and were varied for cancer
cells as a result of circadian disruption. Because the
drug has a short half-life of approximately 10–
20 minutes, no PK model was considered and drug
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exposure of the tissues was assumed to be similar to
administration profiles. The 5-FU cytotoxicity was
represented as an increase in the probability of cells in
S-phase to exit the cell cycle at the G2/M checkpoint. In
this model, 5-FU chronotolerance was driven by the
proportion of cells in S-phase and was lower for drug
administration at 4:00 AM for a cell cycle of 24 hours.
The authors further investigated the effect of intercel-
lular variability in cell cycle phase durations.Maximum
5-FU efficacy obtained for optimal circadian time of
administration increased with cell cycle desynchroniza-
tion within a cell population because the fraction of cells
in S-phase was always larger than at the optimal time
in well-synchronized populations. This theoretical find-
ing provided a theoretical rationale, which further
supported chronotherapeutics, as tumor tissues often
escape from the circadian control responsible for
synchronization.
Another work aimed to develop a physiologically-
based model of 5-FU PK-PD and their circadian control
in humans (Lévi et al., 2010). The model represents
5-FU plasma administration and further degradation
by hepatic dihydropyrimidine dehydrogenase, the drug
cellular uptake and active efflux (ABCC11), intracellu-
lar metabolism into the active metabolite fluorodeox-
yuridine monophosphate (FdUMP) through thymidine
kinase (TK), and reversible binding of FdUMP to
thymidylate synthase (TS). The coadministration of
leucovorin is represented through its intracellular
active compound methylene tetrahydrofolate, which
stabilizes FdUMP-TS complexes into irreversible ter-
nary complexes. Drug-induced overexpression of efflux
pumps is also represented through the activation of a
generic nuclear factor enhancing ABC transporter expres-
sion.Circadianrhythmsareassumed indihydropyrimidine
dehydrogenase and TS protein activities.
C. Toward Personalized Chronotherapeutics: from
Biomarkers to Personalized Chronomodulated Infusions
Modeling anticancer drug chronoPK-PD and action
on cell populations or tissues constitutes the first pre-
clinical step toward the design of clinically-relevant
physiologically-based models. Indeed, mouse-to-human
scaling methods already exist and are undergoing
further development, to help design human models
based on validated in vivo–in silico circadian studies.
Sensitivity analysis performed on such generic clinical
models informs on the key determinants of anticancer
drug chronotoxicity and chronoefficacy to be further
investigated to obtain patient-specific chronoPK-PD
models. Hence, such modeling approach can integrate
the continuous recording of key circadian parame-
ters and tumor-related markers to account for CTS
disturbance and disease evolution in therapeutics
optimization for a given patient. Those continuous
circadian individual datasets combine to patient gen-
eral information (age, sex, lifestyle habits, chronotype,
concomitant medications...), clock and pharmacology
gene polymorphisms, cancer stage, phenotype, and mo-
lecular characteristics. Such multidimensional features
can be integrated into dedicated physiologically-based
models enabling patient-tailored anticancer chronother-
apy computation on a real-time basis.
Thus, the quest for personalized chronotherapeutics
has favored the development of Domomedicine plat-
forms, allowing for the continuous monitoring of circa-
dian and disease-specific markers in nonhospitalized
patients. A first successful conceptual, technological,
and clinical investigation was conducted within the
European Project InCASA (http://www.incasa-project.
eu) in 31 metastatic cancer patients on treatment
(Innominato et al., 2016a). Self-measured body weight,
self-rated symptoms using theM.D. Anderson Symptom
Inventory, and circadian rest-activity rhythm recording
with a wrist-accelerometer (actigraph) were transmit-
ted daily by patients to a server via the Internet, using a
dedicated platform installed at home, over an average
duration of 58 days. The French State supported
PiCADo project and then developed a mobile multiuser
and multipathology telecommunicating platform, fit for
the monitoring of individual patients’ parameters at
home (Maurice et al., 2015). The platform integrates
several lightweight and portable technologies made
interoperable (sensor, collector, geolocation watch, dig-
ital tablet, digital pen collector, information systems,
electronic health records), to allow noninvasive and
automatic collection of different markers of biologic
rhythms (activity, position, temperature) and health
status of the patient (body weight, self-rated symptoms,
and quality of life, etc.) at home or during his or her
daily activities. Authorized users can access record
information via a secure web interface, add different
type of patient information (health, nutrition, psychol-
ogy, etc.), and communicate with other caregivers via
the same interface. Automatic preanalysis of data is
coupled to notifications sending to care professionals,
which they can reset. According to the data, professional
caregivers can also propose adapted dietician or psy-
chologic support services to their patients. The PiCADo
project has also allowed the design of the PiCADomo
clinical study, which aims to establish the first multi-
dimensional database on the health relevance of circa-
dian rhythms, measured in real-life condition in people
receiving complex circadian chemotherapy outside the
hospital.
VI. Systems Chronotherapeutics for
Other Pathologies
In this study, we review published mathematical
works aiming at improving pharmacotherapies of im-
munologic, inflammatory, cardiovascular, and meta-
bolic diseases. There has been no chronotherapeutics
modeling for psychiatric diseases to the best of our
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knowledge, despite bipolar and other mental disorders
having inspired dynamical modeling or chaos theory
applications, resulting in original physiopathological
perspectives (Goldbeter, 2013; Kupfer et al., 2015).
A. Rheumatology and Immunity
Tight links exist between the CTS and the immune
system, as multiple immunologic processes, such as
susceptibility to infection, immune cell recruitment, or
systemic proinflammatory cytokine levels, are under
circadian control (Geiger et al., 2015; Labrecque and
Cermakian, 2015). Daily variations in the intensity of
symptoms of diseases involving the immune system
have also been reported, as in rheumatoid arthritis and
osteoarthritis (Geiger et al., 2015; Labrecque and
Cermakian, 2015). Anti-inflammatory medications rep-
resent a main therapeutic class to combat those rheu-
matologic diseases, and the circadian drug timing plays
a crucial role for their pharmacokinetics, tolerability,
and efficacy. For instance, evening dosing resulted in
both lowest Cmax or Cmax/Tmax (absorption estimate)
and least toxicities for nonsteroidal anti-inflammatory
drug indomethacin or ketoprofen both in healthy sub-
jects and in osteoarthritic patients (Clench et al., 1981;
Guissou et al., 1983; Lévi et al., 1985; Ollagnier et al.,
1987). These findings led to an investigation of the
clinical relevance of dosing time for an oral sustained-
release form of 75 mg indomethacin (Chrono IndocinR)
in patients with osteoarthritis of hip or knee. Overall,
517 patients participated in one of four randomized
multicentre crossover trials, including a placebo-
controlled double-blind study. Each patient took a
single oral dose of indomethacin sustained release in
the morning, at noon, and in the evening for 1 week
each. Adverse events and pain control were the main
endpoints. The incidence of gastrointestinal or central
nervous system–related adverse events was nearly
fivefold as large after morning as compared with
evening dosing in each trial (35 versus 7%). As a result,
the rate of toxicity-related treatment withdrawals was
threefold as high following morning as compared with
evening indomethacin sustained release intake. In
contrast, optimal pain control varied according to the
daily pain pattern. The patients with a typical mechan-
ical pain predominating in the early evening benefitted
most from morning or noon intake. In contrast, those
patients whose pain had an inflammatory component,
as revealed by an early morning exacerbation or an
arrhythmic profile, benefitted most from evening dos-
ing (Lévi et al., 1985; Reinberg and Lévi, 1987). The
results emphasized the need to consider pain dy-
namics, as a disease-related circadian biomarker, to
jointly optimize tolerability and efficacy in individual
patients.
Rheumatoid arthritis is an inflammatory disease
associated with joint pain and stiffness. Disease symp-
toms display circadian rhythms as they tend to be more
severe in the morning (Buttgereit et al., 2015). Such
variations have been correlated in rheumatoid arthritis
patients with overnight increases in the systemic levels
of proinflammatory cytokines that usually peak in the
early morning. This finding led to the development of
several efficient modified-release prednisone formula-
tions achieving circadian drug exposure starting near
the middle of the night span, after an administration
at bedtime (Buttgereit et al., 2015). Indeed, a multi-
centre double-blind randomized clinical trial involving
288 rheumatoid arthritis patients confirmed a better
pain and stiffness control of chrono-released prednisone
as compared with the conventional morning predni-
sone, with statistical significance (Buttgereit et al.,
2008). Other disease-modifying drugs such as metho-
trexate were also shown to be better tolerated and more
effective in patients, following evening dosing (To et al.,
2011).
The molecular mechanisms underlying rheumatoid
arthritis symptoms were amenable to mathemati-
cal modeling based on the circadian control of key
components of the neuroendocrine–immune system
(Meyer-Hermann et al., 2009). The model represents
the interplay between cortisol, noradrenaline, and
tumor necrosis factor (TNF)-a dynamics at the whole-
body level. Theoretical therapeutic predictions sup-
ported best efficacy of glucocorticoids regarding
inhibition of TNF-a secretion following their delivery
between midnight and 2:00 AM, that is, at a time
when this cytokine started being released in the
circulation. Interestingly, this optimal timing corre-
sponded to a drug administration during the early
increase of TNF-a plasma level rather than around its
peak value.
Rheumatoid arthritis is under circadian control, but
the disease can also disrupt the CTS. In a mouse model
of arthritis, both the circadian rhythms in PER2 protein
in the synovial cells of foot joints and the clock gene
transcription patterns in the spleen were strongly
altered as compared with healthy mice (Labrecque
and Cermakian, 2015). Interactions between the CTS
and cartilages occur through multiple molecular
processes both at the systemic and local levels in
healthy conditions (Buttgereit et al., 2015; Yang and
Meng, 2016). Anti-inflammatory treatments can also
profoundly alter the CTS as a function of dose and
timing. Indeed, the delivery of glucocorticoids at early
night suppressed the endogenous cortisol secretion,
resulting in functional adrenal insufficiency. The intake
of a single dose of indomethacin ablated most cognition,
performance, or physiology rhythms following morning
intake, whereas 10 of 11 measured rhythms were
maintained following evening dosing (Clench et al.,
1981). Taken together, the personalization of rheuma-
tologic disease management represents a clinical chal-
lenge involving the interplay of several physiologic
systems and their chronopharmacological control. Such
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complex multiscale problem may greatly benefit from
systems approaches integrating patient-specific fea-
tures of both diseased tissues and drug chronoPK-PD
using the same modeling approach developed for
cancer (reviewed in Cancer as a Driver for Systems
Chronotherapeutics).
B. Cardiovascular Diseases
Marked circadian rhythms characterize most physi-
ologic, biochemical, and molecular parameters that
impact on the cardiovascular system. These include
heart rate; blood pressure; peripheral vascular resis-
tance; blood volume; circulating and intracellular con-
centrations of potassium, sodium, and other ions; and
circulating plasma levels of proteins and albumin, as
well as clock genes and clock-controlled genes and
proteins in heart and arteries (Portaluppi andHermida,
2007; Smolensky et al., 2016). Such circadian organiza-
tion translates into predictable daily changes in the
occurrence of many cardiac events. For instance, most
hypertension bouts, cardiac arrhythmias, myocardial
infarction, or sudden cardiac death happen in the
morning in the general population (Portaluppi and
Hermida, 2007; Smolensky et al., 2016). However, we
are lacking a mechanistic understanding of the CTS
alterations that contribute to cardiovascular patholo-
gies. Statistical and mathematical modeling ap-
proaches have started addressing this challenge.
Fijorek et al. (2013) developed a model investigating
the influence of calcium, potassium, and sodium circa-
dian rhythms on the electrocardiogram and resulting
interval between the start of the Q wave and the end of
the T wave in the heart’s electrical signal (QT). They
concluded that potassium daily variations had the most
significant effect on QT circadian rhythms compared
with sodium and calcium, thus advocating for its choice
as a potential circadian biomarker of the cardiovascular
system.
The efficacy of several medications against cardio-
vascular diseases varied largely according to the circa-
dian time of administration (Portaluppi and Hermida,
2007; Smolensky et al., 2015a), although differences
between subgroups of patients receiving morning or
bedtime drug administration have not been universally
observed (Stranges et al., 2015). Indeed, most drugs
against hypertension achieved both greater improve-
ment of blood pressure circadian profile and lower
risks of cardiovascular events, following their oral
intake at bedtime compared with morning administra-
tion (Smolensky et al., 2016). Several physico-chemical
studies further developed modified release formulation
of valsartan to achieve late night/early morning expo-
sure after a bedtime administration (Kshirsagar et al.,
2011; Biswas and Kuotsu, 2017). Classic PK-PDmodels
have been developed for cardiovascular medications
linking drug dose or plasma concentration to their effect
on the QT interval in an empirical manner, and
modeling efforts have been made to extend them to
account for the circadian control of the drug effect
(Piotrovsky, 2005; Huh and Hutmacher, 2015). More
recently, mixed-effect models were further used to
predict the drug-induced QT prolongation, and model-
ing reliability was improved when integrating daytime
variations (Huh and Hutmacher, 2015). A similar
approach was used to study the effect of three com-
pounds on QRS and PR intervals in dogs (Bergenholm
et al., 2016). Interestingly, taking into account circadian
rhythms improved the fit for the PR model, but not for
QRS modeling. Such empirical models provide hints for
the design of more detailed mechanistic ones. The
subsequent development of a systems approach to the
chronotherapeutics of cardiovascular diseases should
expectedly help design personalized circadian adminis-
tration algorithms.
C. Metabolic Diseases, Diabetes, Obesity
Energy metabolism is under the control of the CTS at
multiple scales, as both systemic factors driven by
the SCN and cellular clocks regulate key metabolic
processes (Sukumaran et al., 2010; Oster et al., 2016).
Many disorders in glucose regulation, such as diabetes
(Qian and Scheer, 2016) or obesity (Laermans and
Depoortere, 2016), and their pharmacotherapies are
also under robust circadian control. Recently, systems
approaches have aimed at studying the dynamics of the
circadian processes possibly impacting on energy me-
tabolism. Because white adipose tissue plays a critical
part in many metabolic disorders, Sukumaran et al.
(2011) developed a mechanistic model of the regulation
by the CTS of adipokine expression in those tissues, also
incorporating the glucose/free fatty acid/insulin system
and the activity of methylprednisolone in rats. Circa-
dian oscillations were considered in the transcription of
glucocorticoid receptors, leptin, and adiponectin in the
tissues and in the plasma levels of glucose, free fatty
acid, insulin, leptin, and adiponectin. These quantities
were fitted to experimental results in rats showing
robust circadian rhythms except for adiponectin
(Sukumaran et al., 2011). Such systems approach gave
insights into the molecular mechanisms of methylpred-
nisone chronopharmacology driving the modification of
glucose, free fatty acid, and insulin plasma circadian
profiles after drug administration. The model also
predicted circadian oscillations in those plasma quan-
tities that were not captured in the experiments due to
the small number of sampling times. Regarding di-
abetes, portable pumps or implanted artificial pancreas
are now available to supply insulin along preprog-
rammed patterns (Russell, 2015; Visentin et al., 2015).
Both modeling and statistical efforts are being made to
optimize the insulin administration scheme according
to the patient’s sex, age, and corresponding biologic
rhythms (Klonoff, 2010; Holterhus et al., 2013; Emami
et al., 2016).
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VII. CTS Disruption
Both the disease itself and its treatments can con-
tribute to the disruption of the CTS in patients. We
review in this work the incidence of circadian disruption
and its impact on treatment outcomes and patient well-
being and suggest systems approaches to better un-
derstand the pathophysiological mechanisms leading to
the desynchronization of circadian functions. We fur-
ther review existing behavioral and pharmacological
strategies to strengthen the CTS rhythmicity and co-
ordination, and available mathematical and statistical
tools to personalize them.
A. Disease-Driven CTS Disruption
Chronic diseases may alter the synchronicity of the
CTS by perturbing either the central pacemaker in the
SCN and the physiologic messengers it produces toward
the body, or directly the rhythms of gene expression in
the peripheral organs. Tumor tissues may present
disrupted circadian organization due to genetic or
epigenetic alterations of clock gene expression, leading
to the loss of functional cellular clocks at the single-cell
level and/or the desynchrony of cells within a tissue
(Savvidis and Koutsilieris, 2012; Ortiz-Tudela et al.,
2013). Similar circadian alterations have been de-
scribed in joint tissues of an animal model of rheuma-
toid arthritis (Labrecque and Cermakian, 2015).
At the whole-body level, the modulation of small
proteins constitutively expressed in the SCN, including
ligands of the epidermal growth factor receptor (EGFR)-
1 and -3 receptor family, such as tumor growth factor-a,
epidermal growth factor, and neuregulin-1, respec-
tively, produced inhibitory actions on circadian behav-
iors in laboratory animals (Kramer et al., 2001, 2005;
Snodgrass-Belt et al., 2005). Prokineticin-2 (a form of
vascular endothelial growth factor) and cardiotrophin-
like cytokine (an interleukin-6–like molecule) adminis-
tration abolished rhythmic locomotor activity and other
circadian behaviors that were restored when these
infusions were stopped, supporting the ligand/receptor
hypothesis (Cheng et al., 2002; Kraves andWeitz, 2006).
Moreover, high-throughput transcriptomic and metab-
olomic studies in mice bearing lung adenocarcinoma
xenografts demonstrated that the tumor modified the
circadian rhythms of hepatic metabolism through
proinflammatory response via the signal transducer
and activator of transcription 3–suppressor of cytokine
signaling 3 pathway, this control being independent of
the hepatocyte molecular clocks that were not affected
by the presence of the malignant cells (Masri et al.,
2016).
Furthermore, elevated serum levels of EGFR ligands
and proinflammatory cytokines (i.e., interleukin-6 and
TNF-a) were associated with behavior changes in
cancer patients (Dantzer et al., 2008; Miller et al.,
2008; Reyes-Gibby et al., 2008). In patients with mCRC,
we reported a significant association of fatigue and
appetite loss in those with higher levels of tumor growth
factor-a, an observation that is consistent with the
preclinical model of hypothalamic modulation of circa-
dian behavior related to the EGFR family (Rich et al.,
2005). EGFR tyrosine kinase inhibitors are associated
with a rapid improvement of cancer patients’ symptoms
of well-being and appetite that are consistent with this
model (Natale, 2004; Bezjak et al., 2006). These obser-
vations were prospectively tested in a small study on
the association of normalized rest-activity patterns and
symptomatic improvement in nonsmall cell lung cancer
patients receiving gefitinib (Iurisci et al., 2007). Al-
though elevated proinflammatory cytokine levels ac-
count for about half of cancer patients with altered
circadian function, other mechanisms are most likely
involved, including drug-induced CTS disruption,
blunted synchronizers from disrupted feeding routine,
minimal and untimely light exposure, or circadian
alterations mediated by other brain areas. Hence,
systems medicine approaches encompassing all fac-
tors toward CTS strengthening would not limit their
usefulness to cancer, but could be applied to other
chronic conditions, such as joint (Berenbaum and Meng,
2016), renal (Koch et al., 2009), liver (Tahara and
Shibata, 2016), cardiovascular (Portaluppi et al., 2012;
Smolensky et al., 2015c), metabolic (Asher and Schibler,
2011; Bass, 2012), neurologic (Smolensky et al., 2015b;
Videnovic and Zee, 2015), and psychiatric (Wulff et al.,
2010; McClung, 2013) diseases. Indeed, altered circa-
dian function has been described in several diseases of
the aforementioned systems, and their function has
been shown to be affected by circadian disruption in
otherwise healthy subjects (Reddy and O’Neill, 2010;
Roenneberg and Merrow, 2016).
B. Drug-Induced CTS Disruption
Some medications can be profoundly disruptive to
circadian cycles, including anticancer drugs and agents
used against inflammatory, autoimmune, or metabolic
diseases (Hrushesky et al., 2009; Maier et al., 2009;
Zhang et al., 2009a; Innominato et al., 2014;
Roenneberg andMerrow, 2016). Indeed, a large number
of therapeutic molecules have an impact on the CTS
either through direct intracellular activity in the SCN
or in the peripheral tissues or through interference with
SCN-induced physiologic signaling. Intracellular drug
control implies either direct interference with the
molecular clock such as lithium (Hirota et al., 2012),
or indirect through changes in cellular pathways that
interact with the clock (e.g., double-strand breaks,
glucose metabolism). Supportive care drugs, especially
centrally-acting medicines, can affect circadian func-
tions given the multiple neuromediator receptors
expressed by human SCN neurons (Sprouse, 2004).
However, very few other medications have adverse
effects as toxic as anticancer agents (Dantzer et al.,
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2012; Di Maio et al., 2016). In murine models, 12 anti-
cancer medications have shown to affect the circadian
functions, depending on both the drug dose and timing
(Lévi et al., 2010). For all considered drugs, the dosing
time of minimum circadian disruption corresponded to
that ofminimum toxicities on healthy tissues. In addition,
mice treated with immunotherapy of interferon (IFN)-a
displayed an altered circadian rhythm of locomotor
activity, core body temperature, and clock gene expression
levels in both the SCN and the periphery (Ohdo et al.,
2001; Koyanagi and Ohdo, 2002). The link between
immunotherapy-mediated CTS disturbance and the
resulting effects on the host is intriguing, considering that
early neurobehavioral symptoms, including depressive,
neurovegetative, and somatic (namely, fatigue, anorexia,
and sleep disturbances) complaints, have been docu-
mented in cancer patients receiving immunotherapy with
IFN-a (Capuron et al., 2000, 2002). Furthermore,
baseline-specific vulnerability factors for the development
of IFN-induced symptoms included both pre-existing
sleep disturbances and exaggerated hypothalamic pitui-
tary adrenal axis response to the initial IFN challenge
(Capuron et al., 2003, 2004). In our experience (Ortiz-
Tudela et al., 2014, 2016; Scully et al., 2011; Roche et al.,
2014), chemotherapy administration in humans does not
necessarily induce alteration of circadian rest-activity
and/or skin temperature rhythms.
C. Clinical Impact of CTS Disruption
The relevance of circadian function in health preser-
vation is endorsed by the negative clinical impact of
circadian disruption in several illnesses. We will focus
in this work on cancer, where the largest experience
exists. There are consistent abnormalities of circadian
function associated with cancer and its progression,
which have been reported in patients (Mormont and
Lévi, 1997). For instance, loss of normal diurnal cortisol
patterns, which is associated with more awakenings
during the night, predicts early mortality with meta-
static breast cancer, independent of other prognostic
factors (Sephton et al., 2000). Such cortisol pattern
alteration also bears independent negative prognostic
repercussion in renal, ovarian, and nonsmall cell lung
cancers (Cohen et al., 2012; Sephton et al., 2013; Schrepf
et al., 2015). Thus, persistently elevated or relatively
invariant levels of cortisol may, in turn, stimulate
tumor proliferation via differential gluconeogenesis in
normal and tumor tissues, activation of hormone recep-
tors in the tumor, or immunosuppression (Sapolsky and
Donnelly, 1985; Ben-Eliyahu et al., 1991; Sephton and
Spiegel, 2003; Asher and Sassone-Corsi, 2015; Longo
and Panda, 2016).
Similarly, altered rest-activity circadian rhythm
assessed either before or during chemotherapy through
wrist-actigraphy was associated with worse prognosis
in patients with mCRC (Fig. 9) (Mormont et al., 2000;
Innominato et al., 2009a, 2012; Chang and Lin, 2014;
Lévi et al., 2014). Moreover, in clinical studies involving
patients with diverse cancer types and stages whose
rest-activity rhythm had been measured by objective
parameters derived from wrist-actigraphy, CTS dys-
function was shown to be correlated with subjectively
measured worse multidimensional symptoms and
health-related quality of life by the patient, as well as
with poorer performance status by the physician
(Mormont et al., 2000; Mormont and Waterhouse,
2002; Levin et al., 2005; Innominato et al., 2009a,b;
Grutsch et al., 2011; Su et al., 2015).
Very closely intermingled with activity and rest is the
circadian cycle of wakefulness and sleep (Palesh et al.,
2012). Thus, poor sleep efficiency, evaluated with wrist-
actigraphy, has been shown to predict shorter overall
survival in women with advanced breast cancer (Palesh
et al., 2014). Moreover, mCRC patients complaining of
subjective sleep trouble displayed abbreviated overall
survival too (Innominato et al., 2015), thus supporting
the clinical relevance of proper sleep in cancer patients
(Palesh et al., 2008; Spiegel, 2008; Ancoli-Israel, 2009;
Innominato et al., 2010; Ortiz-Tudela, 2015) and in the
general population (Cappuccio et al., 2010). Nonethe-
less, sleep is not the only patient-reported outcome
measurement showing an independent prognostic effect
in cancer (Efficace et al., 2006, 2008, 2015; Gotay et al.,
2008; Quinten et al., 2009, 2011, 2014; Zikos et al.,
2015). Intriguingly, several of these subjective prognos-
tic measures reflect functions with relevant synchro-
nizing influence on the CTS, such as social life, physical
activity, or meals (Innominato et al., 2014). Thus,
circadian deregulation, endocrine stress response, and
immune mechanisms seem to create an ensemble of
biobehavioral factors that profoundly impact the tumor
biology at multiple interlocking levels (Sephton and
Spiegel, 2003; Antoni et al., 2006; Eismann et al., 2010).
Subjects suffering from jet lag or intolerance to shift
work might experience fatigue, insomnia or hypersom-
nia, anxiety, depression, distress, irritability, poor
ability to concentrate, reduced vigilance, poor perfor-
mance, both physical and mental, appetite loss, and
dyspepsia (Waterhouse et al., 1997; Drake et al., 2004;
Reid and Zee, 2004; Foster andWulff, 2005;Waterhouse
et al., 2007). These same symptoms are often experi-
enced by cancer patients along the course of their
disease, as a consequence of both the tumor itself and
anticancer chemotherapy, immunotherapy, radiother-
apy, or surgery (Cleeland et al., 2000;Walsh et al., 2000;
Teunissen et al., 2007). Furthermore, cancer patients
are more likely to experience several symptoms at the
same time compared with healthy subjects under
circadian perturbations (Dodd et al., 2004; Chen and
Tseng, 2006; Walsh and Rybicki, 2006; Chen and Lin,
2007). Statistical analysis allowed the identification of
clusters of three ormore symptoms often co-occurring in
patients (Miaskowski et al., 2004; Barsevick et al., 2006;
Dong et al., 2014, 2016; Aktas et al., 2016). The main
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clinical utility of a better understanding of the patterns
of association, interaction, synergy, etiology, and path-
ophysiology of concomitant symptoms producing spe-
cific clinical outcomes (both in terms of prognosis and of
patient-reported functional outcomes) derives from the
possibility of multimodal therapeutic interventions
aimed at relieving the clustered symptoms. Several
studies have explored the prevalence, severity, and
distress of symptoms in cancer patients to better define
symptom clusters sharing a common pathophysiology
(Cleeland et al., 2000; Chen and Tseng, 2006;Walsh and
Rybicki, 2006; Chen and Lin, 2007; Dong et al., 2014).
Despite the different symptom assessment techniques,
the various statistical methods, and the heterogeneous
patient cohorts, it has been found by independent
groups that fatigue, drowsiness, poor sleep, and lack
of appetite, together with anxiety and depression, tend
to show a stronger relationship among them than with
other symptoms (Cleeland et al., 2000; Chen and Tseng,
2006; Walsh and Rybicki, 2006; Chen and Lin, 2007;
Rich, 2007; Innominato et al., 2009b; Aktas, 2013;
Berger et al., 2013). Hence, circadian disruption could
be perceived by the patients with the complaint of this
symptom cluster, and could be a function to be moni-
tored and targeted to relieve them.
D. Systems Approaches To Study Disease and
Drug-Induced CTS Disruption
The precise molecular mechanisms accounting for the
observed effects of diseases and medications on CTS
functions still need to be elucidated. The fact that
medical therapies can elicit the same toxic symptoms
and physiology disturbances induced by the neoplasm
itself ushers to the hypothesis that common pathophys-
iological processes may be involved. Thus, altered
circadian function engenders modifications in other
physiologic functions, including behavioral changes
that lead to blunted synchronizing cues, hence creating
a vicious circle where the CTS is further exposed to
weaker or ill-timed environmental signals. Hence, CTS
disruption needs to be taken into account in the search
for optimal chronotherapeutics regimens. Molecular
mechanisms by which disease and drug exposure influ-
ence all components of the CTS is still a current topic for
mechanistic investigations, and the complexity and
multilevel nature of this challenge advocate for the
use of modeling approaches. Recently, a mathematical
model has been developed linking, at the molecular
level, the circadian clock and its tuning by metabolic
cycles, particularly feeding and fasting behaviors
(Woller et al., 2016). The issue of diet is notably relevant
in cancer chronotherapeutics, for its impact on the
response to anticancer treatment (Bass, 2012; Lee
et al., 2012; Longo and Mattson, 2014; Longo and
Panda, 2016; Sullivan et al., 2016; Vernieri et al.,
2016), among other effects.
Furthermore, a systems biology study investigated at
the molecular level the reasons that DNA damage
arising from ionizing radiation predominantly induces
phase advances of the circadian clock in synchronized
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Fig. 9. Main outcomes of cancer patients according to circadian functioning status, estimated through assessment of rest-activity or salivary marker
rhythms. Left panel: estimated 2-year survival rate (mean + 95% confidence limit) in a total of 1077 cancer patients (Cohen et al., 2012; Innominato
et al., 2012; Lévi et al., 2014; Schrepf et al., 2015; Sephton et al., 2013; Sephton et al., 2000). Right panel: global quality of life domain (mean + standard
error of the mean), derived from the EORTC QLQ-C30 questionnaire, completed by a total of 237 patients with mCRC (Innominato et al., 2009b).
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cell culture, whereas dexamethasone exposure usually
leads to both phase advances and phase delays (Hong
et al., 2009). To understand the underlyingmechanisms
of this nonintuitive result, Hong et al. (2009) explored
several mathematical models representing the intra-
cellular pathways activated byDNAdamage in cultured
cells synchronized with dexamethasone. They con-
cluded that radiation-induced DNA damage activates
the CHK2 kinase that phosphorylates and degrades
unbound PER proteins, but does not interact with PER
in complex with BMAL1/CLOCK dimers. The clock is
thus advanced by two molecular mechanisms, as fol-
lows: 1) unbound PERs are prematurely degraded, and
2) BMAL1/CLOCK continues to be repressed by PER.
Next, the authors studied the autocatalytic positive
feedback loop arising from the fact that the degradation
rate of PER monomers was assumed to be greater than
that of PER as dimers or in complexes with other
proteins in the models. Thus, PER stabilizes itself by
forming complexes that form the basis of an autocata-
lytic process. Including this positive feedback mecha-
nism in the model was in fact mandatory to reproduce
the experimentally observed predominance of phase
advances.
E. Systems Approaches for Coping Strategies: the
Clock as a Target
Based on the findings reviewed above, one main
question arises: are therapeutic interventions targeting
the CTS able to improve health-related quality of life of
patients, together with treatment efficacy and tolera-
bility? This question is yet unanswered, but interest in
this issue is growing and warranted by findings sug-
gesting that stimuli that exert a pacemaker effect on the
biologic clock can influence disease progression. Chro-
notherapeutics may help in strengthening or weaken-
ing the entrainment of the biologic clock to the circadian
environment cues by timely administering the right
stimuli to the patient in need. Behavioral or pharmaco-
logical therapies exert different effects on the CTS and
subsequently on disease progression in different clinical
populations, and sound preclinical research is needed to
give the clinicians molecular targets for interventions
on the CTS (Fig. 10).
This issue cannot be skipped. The light-dark cycle and
many other unavoidable stimuli, such as timing of
meals, of physical activity, and of socio-professional
interactions, exert a synchronizing effect on the biologic
clock. Confirming the classic belief that humans and
their environment are inseparable, it is then impossible
to avoid exposure to environmental stimuli that act on
brain neurotransmitter function and on the transcrip-
tion of clock genes, thus exerting a pacemaker effect on
the CTS (Benedetti et al., 2007). Because most diseases
and their treatments are influenced by these stimuli, a
strict control of the exposure to Zeitgeber should be
recommended in patients.
1. Behavioral Synchronizing Strategies. The easi-
ness to act on the circadian clock machinery via the
manipulation of the light-dark and sleep-wake cycles
has led to the development of a variety of therapeutic
techniques currently used in the treatment of psychiat-
ric conditions, for example, light therapy, dawn simu-
lation, total or partial sleep deprivation, and sleep
phase advance (Wirz-Justice et al., 2005). Interestingly,
preliminary data indicate a potential benefit of these
therapies in cancer as well (Neikrug et al., 2012; Jeste
et al., 2013; Redd et al., 2014). These techniques are
devoid of serious side effects, and could then be easily
translated to other medical conditions.
The design of a theoretical framework is to optimize
the sleep and light scheduling toward rapid circadian
resynchronization of body functions. First, the control of
light exposure on the molecular clock was theoretically
investigated in Drosophila Melanogaster (Bagheri
et al., 2008). Using a dynamical mathematical model
of the molecular circadian clock, the authors deter-
mined the most sensitive molecular targets to entrain
the clock and concluded that, although light was a
strong synchronizer, directly acting on clock gene
transcription and mRNA degradation model parame-
ters may be even more effective. Regarding light
entrainment, the model predicted that to correct initial
phase differences between the subject’s internal time
and the environment of 0 to 9 hours (i.e., to induce a
phase delay), daylight is most effective at the end of the
day. On the opposite, to correct initial phase differences
of 0 to 26 hours and thus to induce phase advances,
daylight is most effective at the start of the day. Roberts
et al. (2016) further investigated the functional contri-
butions of different populations of cellular oscillators for
light entrainment in Drosophila whole-brain explants.
Both their experimental and theoretical works con-
cluded that strong circadian cellular oscillators support
robust overall synchrony in constant darkness, whereas
weaker oscillators facilitate light-induced phase shift in
the network synchrony through transient cell-cell
desynchrony and damped amplitude at the single-cell
level.
Of note, in contrast to flies, themammalianmolecular
clock is not directly light sensitive (Roberts et al., 2016).
Yet, similar results were observed in mouse SCN and
lung extracts, showing that lung cells were entrained to
various Zeitgeber cycles, whereas SCN neurons were
not (Abraham et al., 2010).Mathematical investigations
validated through dedicated experiments concluded
that strong cell-to-cell network coupling in the SCN
explained these tissue-specific entrainment properties
rather than cellular differences. Further pluridiscipli-
nary investigations have shown that the neurotrans-
mitter GABA was central in synchronizing circadian
rhythms among individual SCN neurons (DeWoskin
et al., 2015). Also, several systems biology approaches
intended to explain the singularity behavior in which
Systems Chronotherapeutics 189
robust circadian oscillations of a cell population can be
abolished after a single stimulus, such as a light or
temperature pulse, applied at the appropriate timing
and intensity. They demonstrated that singularity
behavior arises from the loss of synchronization of the
cellular oscillators rather than from arrhythmicity of
each individual molecular clock (Ukai and Ueda, 2010).
In the context of jet lag arising from travel across time
zones, Dean et al. (2009) have proposed a semimechan-
istic mathematical model of the circadian pacemaker
aiming to design sleep- and light-based countermea-
sures that allow a rapid alignment of the CTS with the
new environment schedule. The developed algorithms
allowed for the design of optimal behavioral strategies
achieving rapid circadian re-entrainment and subse-
quent improvement of neurobehavioral performance.
More recently, the same model was used in an optimal
control investigation to optimize light exposure and
avoidance for efficiently re-entraining the human CTS
(Serkh and Forger, 2014).
Meal timing is also an effective mean to entrain the
CTS. In rodents, it has been shown that regularly time-
restricted feeding can shift the molecular clockwork in
peripheral tissues (Damiola et al., 2000; Challet et al.,
2003; Shibata et al., 2010; Sherman et al., 2012; Longo
and Panda, 2016). Moreover, in mice exposed to chronic
jet lag conditions, restricted feeding time was able to
improve CTS function, with increased amplitude of
temperature circadian rhythm (Wu et al., 2004). This
phenomenon was associated with a partial rescue of
the more rapid tumor growth induced by photic func-
tional CTS disruption (Wu et al., 2004). Anorexia is
also a prevalent affliction ensued by cancer patients,
and those with circadian disruption and other chronic
conditions at large (Foster andWulff, 2005; Innominato
et al., 2009b). In cancer, appetite can be increased and
the development of cachexia delayed, through the use
of a novel ghrelin mimetic anamorelin, with proven
orexic effects (Temel et al., 2016). Furthermore, so far
preclinical, approaches have been proposed to stimu-
late appetite and energy intake in cancer cachexia,
for example, using melanocortin 4 receptor antago-
nism (Dallmann et al., 2011; Peter et al., 2013). These
pathways could be further exploited to manipulate
appetite and promote optimal food intake timing
(Shibata et al., 2010; Mattson et al., 2014; Zarrinpar
et al., 2016).
2. Pharmacological Synchronizing Strategies. Such
behavioral interventions may be supplemented with
pharmacological therapies. Although old and novel
Fig. 10. Available behavioral and pharmacological strategies to restore circadian rhythms in patients. The timing and regularity of bright light
exposure, physical exercise, social and family life, and sleep-wake routine affect the function of the central clock, whereas the fasting-feeding schedule
impacts on metabolism-linked peripheral clocks. Novel synthetic agonists or modified-release formulations of the hormones melatonin (e.g., Ramelteon,
Tasimelteon, Agomelanine) and cortisol (e.g., delayed-release prednisone) can be used to target the central clock, as well as the peripheral oscillators in
tissues equipped with the specific receptors. Several drugs used to treat psychiatric conditions, thus affecting neuronal function in the central nervous
system, such as lithium, selective serotonin-uptake inhibitors, anxiolytic and hypnotic GABA agonists, or novel sleep inducers like the orexin-
antagonist Suvorexant, can directly or indirectly modulate the function of the central clock, because SCN neurons are equipped with receptors of these
drugs, or receive neuronal input from other brain areas affected by these drug classes. Finally, recent small molecules targeting core proteins of the
circadian molecular clock modify their activity and thus impact circadian functions; these include REV-ERB agonist, CK1 inhibitor, SIRT1 agonist, and
CRY activator.
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sleep inducers can improve sleep in selected popula-
tions (Rajaratnam et al., 2009; Lemoine and Zisapel,
2012; Kuriyama et al., 2014; Michelson et al., 2014;
Lockley et al., 2015; Innominato et al., 2016b; Liu et al.,
2016;Wilt et al., 2016), cancer patients, sick people with
other conditions, and the general population suffering
from sleep troubles seem to benefit from the concomi-
tant use of both hypnotic drugs and cognitive and
behavioral therapies (CBT) (Bootzin and Epstein,
2011; Riemann et al., 2011; Langford et al., 2012).
Conversely, CBT for insomnia remains the first-choice
treatment in this setting, in both cancer patients and
subjects with primary insomnia (Trauer et al., 2015;
Johnson et al., 2016). Behavioral interventions yield
better results than pharmacological ones regarding
fatigue management for which encouraging outcomes
have been described with contemplative therapy, tai-
chi, and yoga interventions (Mustian et al., 2007;
Minton et al., 2013; Saligan et al., 2015), whereas
psychostimulants have shown limited activity (Carroll
et al., 2007; Ruddy et al., 2014).
Psychotherapy and pharmacotherapy can be com-
bined to achieve best results in depression. Thus,
alongside antidepressants, CBT, mindfulness, and psy-
chodynamic therapy are routinely used to treat de-
pressive state, either primary or cancer-related
(Hirschfeld et al., 1997; Mann, 2005; Ebmeier et al.,
2006; Dauchy et al., 2013; Craighead and Dunlop, 2014;
Walker et al., 2014). From the circadian perspective, of
particular interest is the demonstration of clinical
activity in refractory bipolar disorder of the interper-
sonal and social rhythm therapy (Frank, 2007; Frank
et al., 2007). This intervention fully integrates the
concept of circadian resynchronization into the man-
agement of psychiatric conditions associated with cir-
cadian disruption and lacks any significant side effect.
Another phase-resetting approach involves the use of
endogenous hormone melatonin, or of its more recent
analogs (Redfern et al., 1994; Geoffriau et al., 1998;
Skene et al., 1999; Touitou and Bogdan, 2007; Cardinali
et al., 2012; Rivara et al., 2015; Liu et al., 2016). A
mathematical model of the circadian endogenous pro-
duction and clearance of melatonin was designed and
incorporates light-induced melatonin suppression and
circadian phase shift (St Hilaire et al., 2007). It also
includes a compartment to model salivary melatonin
levels, which is widely used in clinical settings to
determine circadian phase of individual subject. This
model was recently supplemented to include the PK of
oral exogenous melatonin and phase-shifting effects via
melatonin receptors in the SCN (Breslow et al., 2013). A
more complex physiologically-basedmodel of exogenous
melatonin whole-body PK is also available (Peng et al.,
2013). These models provide comprehensive tools to
optimize melatonin administration and light exposure
schedule and can incorporate patient-specific molecular
features to personalize the resetting strategy.
Finally, specific targeting of the molecular circadian
clock, eliciting different kind and depth of responses,
can be obtained using dedicated molecules, including
agonists or antagonists of core clock genes (Schroeder
andColwell, 2013). Kimet al. (2013) undertook a systems
pharmacology approach to optimize the concomitant
administration of the CK1d/« inhibitor PF-670462 and
light exposure to manipulate the CTS. They designed a
model of the SCN molecular clock incorporating
PF-670462 brain and plasma PK and the drug-induced
inhibition of CK1d/«. The model predictions that were
experimentally validated in mice indicated that chronic
CK1d/« inhibition during the first hours of the LD12:12
cycle leads to a stable delay of activity, whereas the same
drug given toward the end of the light phase, or with
light–darkness schedules involving longer light periods,
does not entrain the host clock.
Most of the above-mentioned interventions have
solely been tested on their own to treat only a single
symptom, and very rarely, maybe with the exception of
interpersonal and social rhythm therapy, with the aim
of restoring a healthy circadian function. However,
given the oftentimes multifactorial pathogenesis of
circadian disruption, and the specificity of each patient,
at any given point of the clinical course of the disease,
for sensitivity to any disrupting factor, it is undeniable
that a systems medicine framework is required for an
improved care of these systemic symptoms. This ap-
proach should integrate both pharmacological manipu-
lations and behavioral changes, with a personalized
plan and predictivemeasures, and include participation
of the patients to their well-being. Indeed, this kind of
groundwork is advocated for the 5P medicine (Gorini
and Pravettoni, 2011; Hood and Friend, 2011; Tian
et al., 2012).
VIII. Conclusions: Expected Benefits and
Challenges of Systems Chronotherapeutics
The delivery of medications according to circadian
rhythms has shown clinical benefits in randomized
trials involving large number of patients with cancer,
rheumatologic, cardiovascular, or allergic diseases.
However, inter- and intrapatient variabilities have
been demonstrated regarding the circadian timing
system that governs chronotherapeutics mechanisms.
Dedicated systems biology/medicine methodologies en-
able such challenges to be handled through the integra-
tion of patient-specific key parameters within a unique
mathematical framework for the design of personalized
pharmacotherapies. Systems chronotherapeutics thus
represent a conceptual and methodological advance for
making chronotherapeutics fit for each individual pa-
tient. As such, it will expectedly greatly impact on
patients’ health due to the joint improvement in tolera-
bility and efficacy, resulting from the moderation of
treatment dynamics by patient- and disease-specific
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parameters, as well as by therapeutic strategy. This is in
sharp contrast with current treatment paradigms, which
remain mostly based on empiricism, standardization,
snapshot assessments, and reactive decisions. Addition-
ally, systems chronotherapeutics will allow for the re-
duction of medical complications due to the delivery of
even complex treatments on a full outpatient basis. The
continuous monitoring of patient well-being and disease
in real time, thanks to dedicated interactive Domomedi-
cine platforms, has nowadays entered clinical evaluation
for cancer. Indeed, the combination of complex chrono-
therapeutic administration at home, with multidimen-
sional telemonitoring, and timely behavioral tutoring
would support chronic disease patients and their families
to enjoy improved daily life, through reduced adverse
events, and better efficacy.
Preclinical and clinical physiologically-based systems
chronopharmacology approaches have highlighted the
need for new quantitative measurements at cell, tissue,
and whole organism scales. PK investigations in mice
have revealed a crucial role of tissue drug concentra-
tions that highly differ according to circadian timing,
whereas plasma PK sometimes showed little differ-
ences. Hence, the sole quantification of plasma drug
levels does not provide the needed information for
chronotherapy optimization. The translation of this
finding to the clinics requires the development of non-
invasive quantitative imaging techniques. Moreover,
physiologically-based models incorporate organ-specific
circadian rhythms of protein activities so that precisely
evaluating those quantities is crucial for model calibra-
tion and subsequent validation. Thus, the development
of reliable quantitative techniques measuring the abso-
lute protein levels and activities on a 24-hour basis is
needed.
The arising of “omics” technologies may have huge
implications for the molecular understanding of the
CTS and its interplay with diseases and treatments,
and for the implementation of personalized chronother-
apy into the clinics. Recent in vitro and in vivo inves-
tigations have provided insights into tissue-specific
circadian organization through transcriptomic, proteo-
mic, and metabolomic circadian datasets (reviewed in
Dallmann et al., 2016; Gumz, 2016). In particular,
systems approaches involving high-throughput preclin-
ical studies in the mouse liver have been useful for
characterizing the circadian molecular determinants of
the clock control on hepatic drug metabolism. Further-
more, circadian “omics” technologies have now been
tested in various biologic samples from laboratory
animals, such as blood, saliva, urine, and exhaled
breath (reviewed in Dallmann et al., 2016). These
investigations present a great translational potential
as such samples can realistically be collected around the
clock in a noninvasive manner in individual patients.
Such large-scale datasets could then be combined,
through systemsmethodologies, with other patient data
such as rest-activity and temperature rhythmic profiles
or genetic polymorphisms toward the prediction of
individualized optimal drug timing.
Pharmaceutical and biomedical industries also have
great interest in endorsing multidisciplinary systems
chronotherapeutic as a cost-effective mean to improve
drug development, which currently has a high failure
rate (Rosenblatt, 2017). Indeed, physiologically-based
mathematical models can be developed to assess
patient-specific drug chronoefficacy and chronotoler-
ability from multitype datasets measured through
dedicated biomedical devices. Thus, this type of model-
ing allows for a priori in silico test of therapeutic
response of individual patients to a specific drug
combination and/or timing, thus providing a critical
tool to assist the clinicians’ decision to include a
particular patient in a clinical trial. Ultimately,
physiologically-based models can be used in optimiza-
tion procedures to design personalization frameworks
taking as inputs multitype datasets in the individual
subject and outputting patient-tailored chronomodu-
lated treatments. After its design though preclinical
and clinical steps, the personalization algorithm needs
to be validated through several clinical stages. As a
result, systems chronotherapeutics represent a new
methodology for the design of clinical trials, in which
each individual patient would receive individualized
chronomodulated therapies computed by data-driven
mathematical models, a novel approach in need of
clinical validation. One of the challenges toward this
clinical progression involves the training of clinicians
and health professionals, to make them fully under-
stand the grounds and clinical potential of systems
medicine approaches. Thus, the European CaSyM proj-
ect has been emphasizing the need for integrating
systems medicine into medical and other medically-
related degrees.
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